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1 Abstract 
Lung cancer is the leading cause of cancer-related death worldwide. 
Approximately 85 % of all lung cancers are histologically grouped as non-small-
cell lung cancer (NSCLC). Besides surgery and chemotherapy, radiotherapy is 
firmly established as an important modality in curative treatment of localized as 
well as locally advanced NSCLC and in palliative care. Nevertheless, systemic and 
localized relapse is frequently observed. Recent developments have led to a more 
refined typing of advanced NSCLC by incorporating biomarkers of oncogenic 
pathway activation. This has allowed the successful introduction of "targeted 
pharmacotherapies" that are better tailored towards biological differences between 
histologically uniform NSCLC entities. In contrast, radiotherapy still does not take 
advantage of biological disease heterogeneity, and radiosensitization protocols are 
empirically derived, rather than based on validated biomarkers. 
Against this background, it was hypothesized that an improved understanding of 
the modulation of the radiotherapy response of NSCLC by signal transduction 
pathways may open new avenues for the development of more specific protocols 
to combine radiotherapy with pharmacotherapies. To this end, a systematic 
assessment of the functional impact of selected regulators of apoptosis, 
oncogenes, and signal transduction mediators on irradiation-induced cell death 
was initiated in a small-scale screen of lung cancer models. 
Anti-apoptotic members of the BCL-2 family have been selected as the first group 
of potential biomarkers for the radiotherapy response in NSCLC. BCL-xL as well 
as MCL-1 conferred resistance against irradiation in A431 cells. Expression of 
both modulators led to decreased radiation-induced cell death and additionally 
gave a competitive edge in clonogenic survival in vitro. Studies obtained by 
radiation therapy of tumor-bearing mice in vivo supported the relevance of BCL-xL 
for radioresistance in an organismal context. Surprisingly, these findings were not 
convincingly explained by BCL-xL and MCL-1 mediating radioresistance by 
inhibition of apoptosis, as radiotherapy induced only negligible amounts of 
apoptosis. Also no impact of BCL-xL on cell cycle kinetics following irradiation was 
observed. Studying the influence of BCL-xL on deoxyribonucleic acid (DNA) 
double-strand break (DSB) repair pathways as a potential effector mechanism 
revealed that BCL-xL-mediated radioresistance relied on functional homologous 
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recombination repair (HRR) and involved enhanced repair through error-prone 
alternative end-joining (alt-EJ). This led to the propagation of cells with gross 
chromosomal aberrations, possibly promoting survival of more resistant and 
aggressive lung cancer subclones. To circumvent this, combining irradiation with 
targeted therapies against anti-apoptotic BCL-2 family members was suggested as 
a useful strategy. Thus, BCL-xL and/or MCL-1 were antagonized on a genetic or 
functional level. These strategies, including shRNA-mediated knockdown, 
conditional overexpression of pro-apoptotic BAK, as well as pharmacological 
treatment with BH3-mimetics, sensitized lung cancer cells to radiotherapy. Based 
on this, it is proposed to select patients with high expression of the respective drug 
targets in recent tumor biopsies for clinical proof-of-principle studies combining 
radiotherapy with pharmacologic antagonists of the BCL-2 family such as 
Navitoclax. 
The signal transduction mediator RAF-1 was identified as the second potential 
biomarker for the radiotherapy response in NSCLC. Conditional activation of 
RAF-1 reduced the number of irradiation-induced cell death significantly. 
Clonogenic survival could not be evaluated as RAF-1 activation itself inhibited 
colony formation in general, possibly due to induction of a cell cycle arrest or 
senescence. It was further shown that activation of RAF-1 even after irradiation 
had still radioprotective effects. The underlying mechanisms remain to be 
elucidated in technically more appropriate models, in particular in vivo. 
In conclusion, two modulators of the radiotherapy response in NSCLC were 
identified and functionally validated. In addition, targeting non-apoptotic functions 
of BCL-2 family proteins was nominated as a novel strategy for biologically rational 
radiosensitization protocols. 
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2 Introduction 
Every year, about 1.8 million people are diagnosed with lung cancer. Therewith, it 
is the most common type of cancer worldwide with highest estimated age-
standardized incidence rates in Central and Eastern Europe as well as Eastern 
Asia (Ferlay et al. 2013). Furthermore, lung cancer is the leading cause of cancer-
related death worldwide, estimated to be responsible for nearly one in five (Ferlay 
et al. 2013). Approximately 85 % of all lung cancers are histologically grouped as 
non-small-cell lung cancer (NSCLC) with adenocarcinoma being the 
predominating subtype. The 5-year survival rate for lung cancer is 17 % on 
average. Localized stages have a 5-year survival of 54 %, but only 15 % are 
diagnosed at those stages. 57 % of all cases are diagnosed at distant stages and 
have a 5-year survival rate of only 4 % (American Cancer Society 2015). This 
emphasizes the significance of research in the field of lung cancer treatment. 
The following chapters present current treatment concepts for NSCLC and the 
molecular basics for radiotherapy. Here, radiation physics, the significance of 
double-strand breaks (DSBs), and different mechanisms for repairing those lethal 
lesions are outlined. This provides the theoretical framework for this thesis. In 
addition, two modulators of radiotherapy response that have been identified in this 
work, namely members of the BCL-2 family and the regulator of signaling RAF-1, 
are described in detail. 
 
 
2.1 Current treatment of non-small-cell lung cancer (NSCLC) 
Current treatment of NSCLC includes surgery, radiotherapy, chemotherapy, and/or 
targeted therapies. Surgery is usually the treatment of choice for NSCLC 
diagnosed at an early stage (stages I/II and IIIA), and is often combined with 
adjuvant chemotherapy. Inoperable early stage tumors are typically treated with 
radiotherapy (Goeckejan et al. 2010). Advanced stages of NSCLC are usually 
treated with multimodal strategies including chemotherapy, radiotherapy, and 
targeted drugs (American Cancer Society 2015; Goeckejan et al. 2010). Combined 
chemoradiotherapy protocols are frequently applied, as some chemotherapeutics 
(e.g. platinum derivates) were shown to have radiosensitizing effects (reviewed in 
Kvols 2005). These combined chemoradiotherapy strategies can lead to response 
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rates of up to 50 %, however they are often accompanied by increased acute or 
chronic side effects, and relapse is frequently observed. Consequently, the 5-year 
survival rate is only marginally increased (Wagner & Yang 2010). 
Molecular stratification of individual tumors has become an important topic in 
NSCLC in the last years. Several driver mutations determining multiple subgroups 
have been identified by comprehensive genomic analyses (Weir et al. 2007; Ding 
et al. 2008; Pao & Girard 2011). These findings led to the successful introduction 
of targeted pharmacotherapies as an important modality in NSCLC treatment 
(Paez et al. 2004; Kwak et al. 2010; Mok et al. 2009; Stöhlmacher-Williams 2012). 
Thus, therapy decisions are not only based on staging, additional diseases, and 
the overall condition of a patient any more (Ausborn et al. 2012), but molecular 
characteristics of tumors define the application of targeted drugs. 
One example for treatment based on molecular characteristics are tumors with 
activating mutations in the epidermal growth factor receptor (EGFR), which are 
found in 10 - 40 % of all NSCLC patients (Kosaka et al. 2004; Paez et al. 2004; 
Shigematsu et al. 2005). In 2004, Paez and colleagues demonstrated that 
response to the EGFR tyrosine kinase inhibitor (TKI) gefitinib is associated with 
mutations in EGFR (Paez et al. 2004). Even more impressively, it was not only 
shown that patients with EGFR mutations in their tumors have a better outcome 
when treated with EGFR TKI (like gefitinib, erlotinib), but patients which are 
negative for EGFR mutations show a better survival when treated with standard 
carboplatin-paclitaxel chemotherapy (Mok et al. 2009; Maemondo et al. 2010; 
Mitsudomi et al. 2010; Fukuoka et al. 2011; Rosell et al. 2012). This is an excellent 
example for the importance of molecular stratification for treatment decisions. 
Besides impressive initial responses of stratified tumors to targeted therapies, 
tumor control is only transient and localized as well as systemic relapse are 
frequently observed. This has been linked to acquisition of additional mutations in 
the drug target, thereby making the drug ineffective, or activation of other signaling 
pathways, which promote tumor progression (Yu et al. 2013). Thus, there is an 
urgent need to develop new, more efficient treatment strategies, which also 
provide a long-term survival benefit. 
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2.1.1 Strategies to improve radiotherapy with targeted drugs 
Radiotherapy is an important modality for curative treatment of localized and 
locally advanced NSCLC as well as in palliative care. For curative treatment, either 
conventional radiotherapy (> 60 Gy total dose, 1.8 to 2 Gy per day, 5 fractions per 
week) or continuous, hyperfractionated, accelerated radiotherapy (CHART, 54 Gy 
total dose, 3 x 1.5 Gy per day on 12 consecutive days) are applied. In palliative 
care, conventional as well as different hypofractionated radiotherapy protocols are 
used depending on general condition and symptoms of the patient (Goeckejan et 
al. 2010). Major limitations of current radiotherapy lie in normal tissue toxicity and 
standard protocols are already administered at the maximum-tolerated doses 
(Morgan et al. 2014). Two strategies are feasible to improve radiotherapy: either 
protecting normal tissue, or sensitizing tumor cells. Both approaches are expected 
to broaden the therapeutic window. 
As radiotherapy response of several tumor entities, including NSCLC, is highly 
heterogeneous, even in clinically and histologically similar tumors, it was 
hypothesized that genetic and epigenetic processes define the tumor’s 
radiosensitivity (Das et al. 2010). In the last decade, molecular signatures of 
radiation response have been investigated tremendously. However, there are no 
validated biomarkers available in NSCLC, yet (Ausborn et al. 2012). Most present 
pre-clinical strategies target either DNA damage response (e.g. via CHK-1 or 
PARP-1) or signaling pathways, with EGFR being extensively investigated. 
Inhibition of EGFR by ZD1839 (Iressa, TKI), erlotinib (TKI) or cetuximab (antibody) 
mediated radiosensitization of tumor cells in vitro and in vivo (Bianco et al. 2002; 
Chinnaiyan et al. 2005; Wang et al. 2011). However, initial clinical trials have 
rather not been successful. Combination of chemoradiotherapy and anti-EGFR 
monoclonal antibodies (e.g. cetuximab) did not result in survival benefit and 
similarly, the combination with EGFR TKI (e.g. gefitinib, erlotinib) only showed 
marginal advantages which were partially accompanied by severe side effects 
(reviewed in Zhuang et al. 2014). 
The major issues of clinical trials with combined treatment modalities are patient 
selection, scheduling and dose of applied therapies, as well as therapy duration. 
Thus, preclinical testing of those parameters and also understanding the molecular 
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mechanisms of radioresistance are a prerequisite of successful future clinical trials 
for biomarker-driven protocols. 
 
 
2.2 Ionizing radiation, DNA damage, and double-strand break 
(DSB) repair 
DNA damage is one major issue a cell has to cope with every day, as cellular 
survival highly depends on the integrity of the carrier of genetic information. 
Modifications and lesions in the DNA occur from physical as well as chemical 
environmental agents, intracellular oxidative stress (as a product of metabolism), 
and scheduled biological processes like DNA replication or V(D)J recombination 
(Mladenov & Iliakis 2011a). The steady-state background of endogenous DNA 
lesions is thought to be at least 50,000 in every cell per day (Swenberg et al. 
2011). To ensure survival nonetheless, cells have evolved a variety of 
mechanisms to repair those modifications and lesions (reviewed in Sancar et al. 
2004). As the majority of those damages are abasic sites or base modifications 
(Swenberg et al. 2011), there is still an undamaged complementary strand in the 
DNA double helix available, which can serve as a template for repair and 
facilitates rather easy repair. 
Ionizing radiation (IR) exposure with a dose of 1 Gy results in only 1000 single-
strand breaks (SSBs), a similar number of base lesions, and about 20 - 40 double-
strand breaks (DSBs) per cell (Ward 1990). In contrast to the everyday DNA 
damage, this number of lesions is rather small. Nevertheless, normal cells 
frequently die from this damage. The reason for this is that those damages are not 
homogenously distributed among the whole genome, but occur as clustered and 
complex damage sites. This is a unique characteristic of IR (Mladenov & Iliakis 
2011a) and is caused by its physical features.  
 
 
2.2.1 Physical background of ionizing radiation (IR) 
Radiation is defined as energy that was emitted from a source and travels through 
space or mass of matter. If the energy of radiation is enough to free electrons from 
atoms and molecules, this radiation is termed ‚ionizing’, as a target becomes 
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charged or ionized by this type of radiation (Hall & Giaccia 2006). Chemically, 
emerging electron loss is equivalent to oxidation (Mladenov & Iliakis 2011a). The 
unit of IR is Gray (Gy) with 1 Gy corresponding to 1 J/kg (Hall & Giaccia 2006). 
IR is generated by either electromagnetic waves of short wave length and high 
frequency (like X-rays and γ-rays, which were used in this thesis) or particles (like 
electrons, protons, α-particles, neutrons, or heavy ions). IR is subclassified into 
‘directly ionizing’ and ‘indirectly ionizing’. Only electrically charged particles are 
directly ionizing, meaning that they carry enough energy to directly interact with 
atomic electrons through coulombic forces, thereby disrupting the atomic structure 
of the absorber and producing chemical or biological changes (Hall & Giaccia 
2006). Radiation that is indirectly ionizing is not able to directly interact with atomic 
electrons, as it is electrically neutral. However, collision with atomic nuclei 
produces charged particles, which cause ionization in a second step. This process 
is called linear energy transfer (LET). LET is defined as energy of an ionizing 
particle transferred to material along the track (keV/µm) (Seltzer et al. 2011). The 
main target for LET is water producing hydroxyl radicals (OH). Two types of LET 
are distinguished: low LET (sparsely ionizing) and high LET (densely ionizing). 
X-rays and γ-rays show mostly low LET, in contrast to this e.g. α-particles possess 
high LET features (Hall & Giaccia 2006).  In general, high LET causes more 
biological effects than low LET (Kadhim et al. 2006). A reason for this might be 
that radiation with high LET produces very large energy depositions in target 
structures, which is unachievable by x- and γ-rays (Goodhead & Nikjoo 1989). 
This indicates that IR with low and high LET differ in their track structures (Figure 
1). Densely ionizing charged particles as well as electrons at the end of their track 
show increased ionization events in a rather small volume (Nikjoo et al. 1994; 
Nikjoo & Goodhead 1991).  
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Figure 1: Schematic drawing of IR tracks through a cell nucleus. (A) High LET track (e.g. from α-
particles). A dose of 1 Gy corresponds to 3 to 4 tracks. (B) Low LET tracks (e.g. from X-ray or γ-rays). A dose 
of 1 Gy corresponds to about 1000 tracks (modified from Kadhim et al. 2006). 
 
 
2.2.2 Double-strand breaks (DSBs) and their repair 
As described above, the unique characteristic of IR is the generation of complex 
and clustered DNA damage. Severity of those clustered lesions comes from their 
reduced reparability compared to individual lesions (Lomax et al. 2013; Eccles et 
al. 2011) and from the finding that multiple lesions affecting both DNA strands and 
localizing in close proximity (within one helical turn) are highly prone to generate 
additional DSBs. Early studies already termed DSBs to be the ‘lesions most likely 
to be the cause of lethal effects of ionizing radiation’ (Ward 1990). This type of 
lesions is defined as a break in the phosphodiester backbone of both DNA strands 
separated by about 10 base pairs or less (Lomax et al. 2013; Hanai et al. 1998). 
Three main scenarios are known that contribute to DSB formation: 1) close 
proximity of two SSBs, which form DSBs promptly, 2) chemical processing of 
sugar lesions, which in their initial form do not disrupt the sugar-phosphate 
backbone, and 3) enzymatic processing of nearby base damage (Mladenov & 
Iliakis 2011a). DSBs are the most severe form of DNA damage for two reasons: 
first, because they are difficult to repair due to the lack of an intact template strand, 
and second, because they disrupt the continuity of the DNA molecule, thereby also 
destabilizing surrounding chromatin and endangering loss of genetic information 
(Mladenov & Iliakis 2011a).  
To allow efficient removal of those complex lesions, repair has to be coordinated 
with other cellular processes. This coordination is triggered by the DNA damage 
response (DDR) and is essential for genomic stability as well as cell survival 
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(Kastan 2008). It comprises a multistep process of sensing DNA damage 
(especially DSBs), signaling damage to downstream pathways, and mediating 
cellular response (Zhou & Elledge 2000). The major players in sensing DNA 
damage are phosphatidylinositol 3-kinase-related kinases (PIKK) including DNA-
dependent protein kinase (DNA-PK), ataxia telangiectasia-mutated (ATM), and 
ATM and Rad3-related (ATR), which are recruited to damage sites by protein-
protein interactions (Sirbu & Cortez 2013). All downstream processes are 
regulated by posttranslational modifications (like acetylation, ubiquitinylation, and 
especially phosphorylation) and protein-protein interactions. DDR includes local as 
well as global changes within the cell and provides an environment for efficient 
repair. It induces chromatin-remodeling to create a permissive local environment 
around the damage to enable repair. Additionally, it impacts several components 
of global cell metabolism, thereby changing transcription, chromosome mobility, 
and deoxynucleotide (dNTP) levels (Sirbu & Cortez 2013). However, the major 
contribution of DDR is inhibition of cell cycle progression and induction of 
programmed cell death (apoptosis), if damaged sites cannot be repaired. 
Repair of DSBs comprises highly sophisticated machineries. This is necessary as 
unrepaired or misrepaired DSBs entail severe consequences for the cell. 
Unrepaired DSBs can induce permanent cell cycle arrest, apoptosis, or another 
type of cell death (Olive 1998), while misrepair can cause mutations, chromosome 
rearrangements, and carcinogenesis (Jackson 2002). Currently, three major repair 
pathways for DSBs, namely homologous recombination repair (HRR), classical 
non-homologous end-joining (c-NHEJ), and alternative end-joining (alt-EJ) are 
known and will be described in a simplified form in the next sections. 
 
 
2.2.2.1 Homologous recombination repair (HRR) 
As already indicated by its name, HRR utilizes homologous DNA strands to repair, 
which enables error-free repair (Mladenov & Iliakis 2011a). It operates in a cell 
cycle dependent manner, because it uses the sister chromatid as the homologous 
segment and this is only available during late S and G2 phase of the cell cycle 
(Lee et al. 1997; Krüger et al. 2004). There is evidence that HRR does not only 
repair DSBs, but is also involved in other processes such as repair of DNA-protein 
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crosslinks (Ide et al. 2008) as well as restart and repair of stalled replication forks 
(Petermann et al. 2010). 
The HRR pathway operates with rather slow kinetics (Mao et al. 2008) and 
consists of five major steps: 1) DNA end-resection to form single-stranded DNA 
(ssDNA) overhangs, 2) stabilization of ssDNA, 3) search for the homologous 
segment and subsequent invasion into the intact strand to form a ‘Holiday 
junction’, 4) DNA synthesis, and 5) final resolution of the strands. Figure 2 
presents those steps in detail including the involved proteins. 
 
 
Figure 2: Schematic drawing of HRR pathway. The five key steps of HRR are presented including proteins 
involved in these processes (modified from Mladenov & Iliakis 2011b).  
 
1) DNA end-resection 
The first step of HRR is mediated by binding of the MRN complex to the break 
(reviewed in Stracker & Petrini 2011). This complex comprises meiotic 
recombination 11 (MRE11), RAD50, and Nijmegen breakage syndrome 1 (NBS1). 
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It induces recruitment of C-terminal binding interacting protein (CtIP) (Sartori et al. 
2007), Bloom’s syndrome protein (BLM) (Nimonkar et al. 2008), exonuclease 1 
(Exo1) (Nimonkar et al. 2008), and breast cancer 1 (BRCA1) (Moynahan et al. 
1999). The conjunction of all those proteins removes terminal nucleotides at the 
5’-ends on both sides of the break, thereby producing long 3’-ssDNA overhangs 
(Paull & Gellert 1998). 
 
2) Stabilization of ssDNA 
To stabilize the processed ssDNA, replication protein A (RPA) heterodimers bind 
to the 3’-overhangs. This protects ssDNA from degradation and prevents formation 
of secondary structures (Wold 1997; Sleeth et al. 2007; Fanning et al. 2006). 
Besides its direct function in HRR, RPA also initiates the DNA damage response 
(DDR) by recruiting the ATR / ATR-interacting protein (ATRIP) complex, which 
induces cell cycle arrest (Cimprich & Cortez 2008; Zegerman & Diffley 2009). 
 
3) Homology search 
The search for the homologous strand during HRR is mainly promoted by RAD51. 
Therefore, RAD51 has to be recruited to RPA-covered ssDNA overhangs. To this 
end, BRCA1, which has bound to the break in the first step, recruits BRCA2, which 
confers RAD51 loading (Thorslund & West 2007). This process is supported by 
RAD51 paralogs, like RAD52 (Mortensen et al. 2009). By this, a RAD51 
nucleoprotein filament is formed and serves as the basis for the homology search 
reaction. After finding the homologous DNA strand, the filament, in interaction with 
RAD54, promotes chromatin remodeling, unwinding of duplex DNA, and strand 
invasion to form a ‘Holliday junction’ (Mazin et al. 2010). 
 
4) DNA synthesis 
In the created Holiday junction, the RAD51 loaded strand displaces the original 
strand from the homologous duplex and builds a displacement loop (D-loop) 
(Jackson 2002; Heyer et al. 2010). This primes for DNA synthesis catalyzed by 
polymerases, which copy sequence information from the undamaged to the 
damaged molecule. 
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5) Final resolution 
In the last step of HRR, resolvase protein complexes resolve the holiday junction, 
anneal the new strand with the original strand (Symington & Holloman 2008; West 
2009), and promote ligation, potentially in conjunction with ligases. However, this 
is still not completely understood. During the final process, gene conversion or 
crossing over can occur (Mladenov & Iliakis 2011a). 
 
 
2.2.2.2 Classical non-homologous end-joining (c-NHEJ) 
C-NHEJ, which is also often called canonical or DNA-PK-dependent NHEJ 
(D-NHEJ), is the predominant pathway for DSB repair in mammals (Rothkamm et 
al. 2003; Mao et al. 2008). Although, it operates with lower fidelity than HRR as it 
mainly just ligates two locally available DNA ends. However, c-NHEJ accepts a 
wide range of DNA end substrate configurations, which makes it quite flexible on a 
mechanistic level (Lieber 2010). 
As it does not depend on homologous sequences, it is able to operate throughout 
the whole cell cycle, but it is not capable to ensure sequence restoration or ligation 
of the ends of the original DNA. This makes it quite error-prone. Regarding kine-
tics, c-NHEJ is much faster than HRR with typical half times of 15 - 30 min 
(Mladenov & Iliakis 2011a; Mao et al. 2008). 
C-NHEJ consists of 3 steps: 1) recognition of the break, 2) processing of damaged 
DNA, and 3) ligation. For a detailed description of involved proteins see Figure 3. 
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Figure 3: Schematic drawing of c-NHEJ. The three key steps of c-NHEJ are presented including the 
involved proteins (modified from Mladenov & Iliakis 2011a). 
 
1) Break recognition 
C-NHEJ is initiated by binding of the Ku heterodimer, consisting of Ku70 and 
Ku80, to the DNA ends surrounding the DSB (Mimori & Hardin 1986; Lieber et al. 
1997; Lieber 2010). 
 
2) Processing of damaged ends 
The Ku heterodimer recruits the catalytic subunit of DNA-dependent protein kinase 
(DNA-PKcs) to form the active holoenzyme DNA-PK (Gottlieb & Jackson 1993; 
Meek et al. 2004). This complex attracts and phosphorylates end-processing 
enzymes, like Artemis, and other substrates. The complex with Artemis possesses 
nuclease activity to process damaged overhangs (Ma et al. 2002). Additionally, 
polymerases are recruited to the break to fill in new DNA to generate blunt DNA 
ends. Polymerases λ and μ seem to be of major importance here, as both are able 
to bind Ku and are quite flexible in template-dependent as well as -independent 
DNA synthesis (Lieber 2010). 
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3) Ligation 
In the last step of c-NHEJ, a complex of ligase IV (LigIV), XRCC4, and XRCC4-like 
factor (XLF) ligate the processed ends to reconstitute integrity of the DNA double-
strand (Leber et al. 1998; Ahnesorg et al. 2006).  
 
 
2.2.2.3 Alternative end-joining (alt-EJ) 
In recent years, a third pathway for DSB repair, which seems to function as 
backup, has been described. This pathway is based on end-joining activities and is 
therefore often termed alternative end-joining (alt-EJ) pathway. The major finding 
contributing to this new pathway was that c-NHEJ mutants were still able to repair 
DSBs although HRR-related proteins were not active (Dibiase et al. 2000; Wang et 
al. 2003; Iliakis et al. 2004). C-NHEJ and possibly also HRR suppress alt-EJ 
(Perrault et al. 2004). Thus, alt-EJ seems to gain functional relevance when these 
standard repair processes fail, globally or locally (Dueva & Iliakis 2013), which 
provides its backup character. 
Alt-EJ is operating much slower than c-NHEJ with typical half times of 0.5 to 20 h. 
Theoretically, alt-EJ is able to operate throughout the whole cell cycle as 
homologous sequences are not required. However, it was shown that repair of 
DSBs by alt-EJ is enhanced in G2 and reduced or abrogated in G1 and resting 
cells, respectively (Wu, Wang, Mussfeldt, et al. 2008; Wu, Wang, Wu, et al. 2008). 
Additionally, there are some studies that claim preferential use of microhomologies 
by alt-EJ pathways (Kabotyanski et al. 1998; Verkaik et al. 2002). As c-NHEJ 
mutants show increased levels of irradiation-induced chromosomal aberrations, 
alt-EJ is suggested to be highly error-prone (Virsik-Köpp et al. 2003). 
Several factors contributing to alt-EJ have been identified, which gave rise to the 
hypothesis that there are several sub-pathways, which compete at each DSB by 
yet undefined parameters (Dueva & Iliakis 2013). Figure 4 presents one concept of 
alt-EJ, which consists of a two-step process including 1) recognition of the break 
and 2) ligation. However, further research is needed to define the precise 
mechanisms of alt-EJ. 
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Figure 4: Schematic drawing of alt-EJ. The two key steps of alt-EJ are presented including the known main 
players (modified from Mladenov & Iliakis 2011b). 
 
1) Break recognition 
During alt-EJ, PARP-1 recognizes and binds DSBs in the first step (Wang et al. 
2006; Audebert et al. 2006; Audebert et al. 2008). Potentially, also the MRN 
complex is involved here, as inhibition of MRE11 in c-NHEJ mutants decreases 
end-joining frequency (Dinkelmann et al. 2009; Rass et al. 2009). Those factors 
might promote DNA end processing before ligation. 
 
2) Ligation 
The ligation step is executed by a complex of XRCC1 and Ligase III, which is 
regulated by PARP-1 (Audebert et al. 2004; Della-Maria et al. 2011). There is also 
evidence for involvement of histone 1 (H1), which enhances PARP-1 activity 
(Rosidi et al. 2008), and Werner syndrome proteins (WRN) (Sallmyr et al. 2008). 
 
 
2.2.2.4 Determinants for DSB repair pathways choice 
Pathway choice for DSB repair is an important topic of current research and only 
the surface of this research area will be touched in the following section. 
As described above, there are three main pathways (HRR, c-NHEJ, and alt-EJ) 
that compete for DSB repair. However, contribution of each pathway for overall 
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repair of DSBs is not equal and depends on several factors, like expression and 
phosphorylation of repair proteins, chromatin modulation for repair factor 
accessibility, availability of homologous templates, and probably also complexity of 
the damage. Furthermore, there are also differences in pathway choice among 
different species and cell types. However, in many cell types of higher eukaryotic 
cells, the major repair pathway is c-NHEJ (Shrivastav et al. 2008; Rothkamm et al. 
2003; Mao et al. 2008). 
The most obvious determinant of pathway choice is the cell cycle as HRR needs a 
homologous template for its repair processes. Thus, HRR is upregulated during S 
and G2 phase when a sister chromatid is available. Nevertheless, end-joining 
pathways also remain active in those phases of the cell cycle (Shrivastav et al. 
2008; Takata et al. 1998). In contrast, both end-joining pathways repair homology-
independently and can operate theoretically throughout the whole cell cycle. 
Besides physical determination of pathway choice throughout the cell cycle, the 
main cell cycle regulators, cyclin-dependent kinases (CDKs), were also shown to 
regulate repair pathways. For example, BRCA2 gets phosphorylated at Ser3291 
by CDKs in M phase, which blocks the interaction between BRCA2 and RAD51 
leading to downregulation of HRR (Esashi et al. 2005). However, mechanisms of 
DDR are able to bypass this cell cycle dependent phosphorylation of BRCA2 after 
irradiation (Shrivastav et al. 2008). c-NHEJ is also phosphorylated in a cell cycle 
dependent manner. For example, irradiation-induced autophosphorylation of 
Ser2056 and Thr2609, which is essential for c-NHEJ, is reduced in S phase cells 
(B. P. C. Chen et al. 2005). 
Additionally, direct competition and protein interaction are suggested as other 
determinants of pathway choice. In line with the competition model is the finding 
that cells with mutant c-NHEJ are still able to repair DSBs, yet with slower kinetics 
and repair defects (Dibiase et al. 2000), which was later found to be executed by 
alt-EJ (Wang et al. 2003). Other groups also observed an increase in HRR in 
c-NHEJ defective cells (Shrivastav et al. 2008; Pierce et al. 2001; Delacôte et al. 
2002). Another study presents direct competition of PARP-1 (involved in alt-EJ) 
and Ku (involved in c-NHEJ) for DSB ends (Wang et al. 2006). As Ku has a higher 
affinity to DSBs than PARP-1, c-NHEJ wins this competition under normal 
conditions and provides the kinetic basis for the backup character of alt-EJ 
(Mladenov & Iliakis 2011a). Moreover, the main players of alt-EJ (e.g. PARP-1 and 
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LigIII) are also involved in repair of other lesions (e.g. SSBs, base damage), which 
are induced upon irradiation to a much higher extent than DSBs (Mladenov & 
Iliakis 2011a) and therewith might be an explanation for the non-dominating role of 
alt-EJ. 
Another suggested central regulator of pathway choice is DNA-PKcs. 
Controversially, elimination of DNA-PKcs increases HRR (Allen et al. 2002), while 
inhibition of DNA-PKcs decreases HRR (Allen et al. 2003). An explanation for this 
could be that inhibited DNA-PKcs is still capable of binding to DNA ends and 
therewith, blocking access of other repair factors (Shrivastav et al. 2008). 
Other potential contributors to pathway choice are highly suggest to exist, but will 
go beyond the scope of this thesis. In summary, pathway choice seems to be 
performed by a complex network of different determinants, and the exact 
mechanisms are not yet understood. 
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2.3 BCL-2 family 
Programmed cell death (apoptosis) is an essential cellular process for 
development, tissue homeostasis, and immunity (Czabotar et al. 2014). 
Deregulation of this process can result in degenerative conditions (if cell death is 
increased) or cancer as well as autoimmune diseases (if cell death is prevented) 
(Cory et al. 2003). The central regulators of apoptosis are proteins of the B-cell 
lymphoma 2 (BCL-2) family (Danial & Korsmeyer 2004). This protein family 
comprises death-promoting as well as death-inhibiting factors and the interplay 
between those opposing family members defines cellular susceptibility to undergo 
apoptosis upon insults (Lee et al. 1999; Cory et al. 2003; Danial & Korsmeyer 
2004). Three different subgroups, which share a varying degree in structural and 
sequence homology, are known: BCL-2-like survival factors, pro-apoptotic effector 
proteins, and pro-apoptotic BCL-2 homology 3 (BH3)-only proteins (for details see 
2.3.1, 2.3.2, and 2.3.3, respectively). The first two subgroups share four BCL-2 
homology (BH) domains (BH1 - BH4), while BH3-only proteins just have the BH3 
domain in common with other family members (e.g. Boyd et al. 1995) (Figure 5). 
Additionally, all BCL-2 family members share a transmembrane (TM) region, which 
targets those proteins to the outer mitochondrial membrane (Moldoveanu et al. 
2014). 
 
 
Figure 5: Schematic drawing of sequence homology of different BCL-2 subgroups. All BCL-2 family 
members share the transmembrane-targeting domain (TM) and the BCL-2 homology 3 domain (BH3). 
Additionally, BCL-2-like survival factors and pro-apoptotic effectors have BH1, BH2, and BH4 domains in 
common (modified from Moldoveanu et al. 2014). 
 
The four BH domains build the BCL-2 core, which folds into a hydrophobic pocket 
(Muchmore et al. 1996; Suzuki et al. 2000; Petros et al. 2001). This is essential for 
interaction with other family members (Sattler et al. 1997; Moldoveanu et al. 2006; 
Czabotar et al. 2014) via binding either the BH3 domain of binding partners or the 
TM region (Moldoveanu et al. 2014). 
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2.3.1 BCL-2-like survival factors 
The BCL-2 gene was identified by cloning the chromosome breakpoint of t(14;18) 
chromosome translocation in neoplastic B cells (Tsujimoto et al. 1984) and was 
associated with early steps of tumorigenesis. Later, other family members educed 
especially from homology studies. To date, six BCL-2-like survival factors are 
known: BCL-2, B-cell lymphoma extra-large (BCL-xL, also known as BCL2L1), 
BCL-w (also known as BCL2L2), myeloid cell leukemia 1 (MCL-1, also known as 
BCL2L3), BCL-2-related protein A1 (also known as BFL1, BCL2L5), and BCL-B 
(also known as Boo, Diva, BCL2L10). 
Mouse genetic studies revealed overlapping functions of different anti-apoptotic 
BCL-2 family members. However, some of them operate in a tissue-specific 
manner, and inactivation of individual genes leads to diverse phenotypes 
(summarized in Ranger et al. 2001; Cory et al. 2003). In general, survival of every 
cell type depends on one or more pro-survival family members, with BCL-xL or 
MCL-1 often being crucial (Czabotar et al. 2014). 
BCL-2-like survival factors promote their anti-apoptotic feature by binding either 
pro-apoptotic BH3-only proteins (Cheng et al. 2001) or activated effector proteins 
to control their pro-apoptotic activity (Fletcher et al. 2008) (for detailed information 
about functional interplay, see 2.3.4). While all anti-apoptotic proteins bind BAX, 
BAK only interacts with BCL-xL, MCL-1, and A1 (Willis et al. 2005; Simmons et al. 
2008). 
 
 
2.3.1.1 BCL-xL and MCL-1 
Studying chicken lymphoid cells in terms of bcl-2-related genes discovered bcl-x 
as having 44 % amino acid identity with murine and human BCL-2 (Boise et al. 
1993). Screening for human BCL-x discovered two different splice variants of this 
gene: BCL-xL, which has a similar size and structure as BCL-2 (Boise et al. 1993; 
Petros et al. 2004), and BCL-xS, which lacks the BH1 and BH2 domains (Boise et 
al. 1993). While BCL-xL inhibits cell death after growth factor deprivation, its 
shorter counterpart antagonizes the anti-apoptotic function of BCL-2 and BCL-xL 
(Kirkin et al. 2004). BCL-xL is targeted to the outer mitochondrial membrane by its 
C-terminal transmembrane helix (Zamzami et al. 1998) and seems to be essential 
  
 
2 Introduction 
 
  
26 
for survival, as bcl-x-deficient mice die at around day 13 of gestation having 
anomalies in the development of the brain and hematopoietic tissue due to 
massive apoptosis (Motoyama et al. 1995). 
MCL-1 was originally discovered in maturing human myeloid leukemia cells (ML-1) 
and was proofed to have high sequence similarity with BCL-2 (Kozopas et al. 
1993). MCL-1 expression is critical for multiple myeloma cells (Zhang et al. 2002) 
and like BCL-xL, MCL-1 is also essential for survival as MCL-1 deficiency results 
in peri-implantation lethality (E3.5 - 4) in mice (Rinkenberger et al. 2000). MCL-1 
shares only three BH domains (BH1 - BH3) and the TM domain with other anti-
apoptotic family members. Additionally, it contains a large N-terminal region with 
several confirmed and putative regulatory motifs (Germain & Duronio 2007; 
Thomas et al. 2010). Some of these motifs (like PEST enrichment and arginine 
pairs) are associated with protein lability (Yang et al. 1995). Indeed, MCL-1 has a 
much shorter half-life than BCL-2 and BCL-xL (< 1 h compared to 16 - 24 h) (Yang 
et al. 1995; Maurer et al. 2006). Thus, MCL-1 seems to be tightly regulated in 
terms of transcription, translation, and protein stability (reviewed in Thomas et al. 
2010). 
 
 
2.3.2 Pro-apoptotic effector proteins 
The group of pro-apoptotic effector proteins comprises BCL-2-associated X protein 
(BAX, also known as BCL2L4), BCL-2 antagonist / killer (BAK, also known as 
BCL2L7), and BCL-2-related ovarian killer (BOK, also known as BCL2L9) with 
BAX and BAK being the main apoptosis effectors. They share sequence homology 
with BCL-2 in all four BH domains and also hold a TM domain, which targets them 
to the outer mitochondrial membrane. However, while BAK is permanently located 
at mitochondria (Griffiths et al. 1999), BAX is kept in the cytosol in the absence of 
apoptotic stimuli, as its TM domain is hided in its hydrophobic groove (Suzuki et al. 
2000). Upon cytotoxic signals, BAX and BAK undergo an activating conformational 
change, which uncovers the TM domain of BAX and leads to mitochondrial 
localization of BAX (Gross et al. 1998). Furthermore, the conformational change 
induces homo-oligomerization of both proteins (Gross et al. 1998; Dewson et al. 
2008) and therewith, permeabilization of the outer mitochondrial membrane by 
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either forming channels themselves (Schlesinger et al. 1997), interacting with 
channel-forming proteins (Tsujimoto & Shimizu 2000; Zamzami & Kroemer 2001) 
or forming supramolecular openings different from discrete protein channels 
(Kuwana et al. 2002). The detailed mechanism of BCL-2 family protein interaction 
and apoptosis-induction is described in 2.3.4. 
 
 
2.3.3 Pro-apoptotic BH3-only proteins 
In mammalian cells, ten or more BH3-only proteins have been identified (Kirkin et 
al. 2004) and serve as upstream sentinels that convert specific, proximal death 
and survival signals into cellular outcome (Danial & Korsmeyer 2004). Some 
examples are: BCL-2-associated agonist of cell death (BAD, also known as 
BCL2L8), NOXA (also known as PMAIP1), BIM (also known as BCL2L11), BH3 
interacting domain death agonist (BID), and BCL2 binding component 3 (BBC3, 
also known as PUMA). They are often described as ‘sensors’ or ‘mediators’ of 
apoptosis (Kirkin et al. 2004) as they are not able to induce apoptosis in the 
absence of effector proteins (Zong et al. 2001). Moreover, most of them have dual 
functions by activating BAX and BAK upon death signals and neutralizing BCL-2-
like survival factors (Wei et al. 2000; Letai et al. 2002; Cory et al. 2003; L. Chen et 
al. 2005; Kuwana et al. 2005; Willis et al. 2007). 
Transcriptional control or posttranslational modifications normally constrain the 
pro-apoptotic activity of BH3-only proteins (Zha et al. 1996; Oda et al. 2000; 
Nakano & Vousden 2001). Different cytotoxic signals induce transcriptional 
upregulation, posttranslational modifications and/or relocalization of particular 
BH3-only proteins, which then extend their full pro-apoptotic potential (reviewed in 
Adams & Cory 2007; Happo et al. 2012). For example, BIM is upregulated in 
response to kinase inhibitors and microtubule-stabilizing drugs (Happo et al. 
2012). 
BH3-only proteins interact with pro-survival proteins via the BH3 amphipathic helix 
and the hydrophobic groove, respectively (Czabotar et al. 2014). Minor differences 
in BH3 domains and grooves lead to different binding affinities. While some BH3-
only proteins (like BIM, tBID (cleaved active form of BID) and PUMA) can interact 
and neutralize all BCL-2-like proteins, other BH3-only proteins (like BAD and 
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NOXA) selectively bind only specific pro-survival factors (L. Chen et al. 2005; 
Kuwana et al. 2005; Happo et al. 2012). 
Individual BH3-only proteins seem to be not essential for survival, as loss of them 
(except of BIM), does not change a cellular phenotype, at least in the absence of 
stress signals (Happo et al. 2012). 
 
 
2.3.4 Complex interaction network regulating apoptosis 
The net balance between BCL-2-like pro-survival proteins and pro-apoptotic BH3-
only proteins decides about survival and death (Kirkin et al. 2004). Consequently, 
it seems to be a simple competition model that regulates apoptosis mediated by 
diverse interactions (Czabotar et al. 2014). Several studies have developed 
different models of interaction processes contributing to apoptosis. 
In the ‘direct activation model’ (Letai et al. 2002; Kuwana et al. 2005; Chipuk et al. 
2010), BH3-only proteins are grouped into ‘activators’ and ‘sensitizers’. Activators 
(e.g. BIM, tBID) are thought to directly bind effector proteins like BAX and BAK, 
which triggers their conformational change resulting in homo-oligomerization and 
induction of apoptosis. Sensitizers (e.g. BAD) interact with BCL-2-like survival 
factors, which sequester BAX and BAK in the absence of stress signals. Binding of 
sensitizers leads to release of BAX and BAK resulting in their activation. 
This second sensitizer role of BH3-only proteins, is thought to be their essential 
function in the ‘indirect activation model’ According to this model, BCL-2-like 
proteins antagonize BAK and BAX by binding them, and this antagonism is 
abrogated by BH3-only proteins similarly binding to survival factors (L. Chen et al. 
2005; Willis et al. 2005; Willis et al. 2007; Uren et al. 2007). 
Recently, a ‘unified model’, which describes the complex network of interactions, 
was designed (Llambi et al. 2011; Moldoveanu et al. 2014) and is presented in 
Figure 6. In the unified model, the interaction equilibrium of pro-survival proteins, 
BH3-only proteins, and pro-apoptotic effector proteins defines an anti-apoptotic 
threshold. In the absence of stress signals, effector proteins are inhibited by pro-
survival factors, which also interact with BH3-only proteins leading to reciprocal 
inhibition. In the presence of cytotoxic conditions, BH3-only proteins get 
upregulated or posttranslationally activated. If this exceeds the threshold, anti-
  
 
2 Introduction 
 
  
29 
apoptotic interactions get out of the equilibrium and change into a pro-apoptotic 
state. In this state, BAX and BAK are released from BCL-2-like factors as BH3-
only proteins sequester those. Additionally, binding of BH3-only proteins to BAX 
and BAK further activates them. Activation of effector proteins triggers the so-
called MOMP (mitochondrial outer-membrane permeabilization). MOMP leads to 
release of apoptogenic factors, especially cytochrome c, which activate the 
downstream caspase cascade leading to apoptosis (Zou et al. 1997; Kluck et al. 
1997; Li et al. 1997). 
 
 
Figure 6: Schematic drawing of interaction of BCL-2 family members in the unified model. The balance 
between BH3-only and BCL-2-like proteins determines the threshold for induction of apoptosis. In the absence 
of apoptotic stimuli (left), BLC-2-like proteins inhibit BH3-only proteins as well as effector proteins (BAX/BAK), 
thereby preventing mitochrondrial outer-membrane permeabilization (MOMP). In the presence of apoptotic 
stimuli (right), BH3-only proteins get upregulated or post-translationally activated. This leads to increased 
inhibition of BCL-2-like proteins, which release BAX/BAK, and additional activation of BAX/BAK. This 
promotes MOMP and subsequent caspase cascade activation leading to apoptosis. Black arrows: 
predominantly active, gray arrows: predominantly inactive (modified from Moldoveanu et al. 2014). 
 
 
2.3.5 BCL-2 family and cancer 
Evasion of programmed cell death (apoptosis) is one of the hallmarks of cancer 
(Hanahan & Weinberg 2000) and tumor cells evolve a variety of strategies to 
circumvent cell death (Hanahan & Weinberg 2011). One of those circumvention 
strategies is deregulation of BCL-2 family members, which is frequently observed 
during tumorigenesis (Strasser et al. 1997). In several types of cancer, BCL-2-like 
pro-survival factors are upregulated and function as oncoproteins, while anti-
apoptotic family members are downregulated or lost and therewith, have tumor 
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suppressor features. Both contribute to tumor initiation and progression (Kirkin et 
al. 2004; Amundson et al. 2000). However, not only direct mutations of BCL-2 
family genes lead to deregulation, also a variety of other deregulated signal 
transduction pathways results in deregulated expression of BCL-2 family members 
(Sherr 2001; Kirkin et al. 2004). 
Activation of the BCL-2-regulated apoptosis pathway seems to be crucial for the 
therapeutic efficacy of most current therapies, including conventional cytotoxic 
agents as well as targeted therapies, although cancer treatments can induce 
different types of cell death (Czabotar et al. 2014). Accordingly, several studies 
have demonstrated that BCL-2 family deregulation entails development of 
resistance against diverse therapy strategies, including cytotoxic chemotherapy, 
antibody-based therapy, kinase inhibitors, and immunotherapy (Wesarg et al. 
2007; Meiler et al. 2012; Stolz et al. 2008; Kasper, Breitenbuecher, Reis, et al. 
2012; Kasper, Breitenbuecher, Heidel, et al. 2012; Huber et al. 2005; Ravi et al. 
2006; Hähnel et al. 2008; Kutuk & Letai 2008). There are also few studies which 
show that BCL-2 family members, especially BCL-2, mediate radioresistance 
(Gilbert et al. 1996; Lee et al. 1999; Condon et al. 2002). 
The most important deregulated factors seem to be BCL-xL and MCL-1, which are 
amplified in many different tumors (Beroukhim et al. 2010). In NSCLC, 
approximately one third of cases exhibits strong expression of anti-apoptotic 
BCL-2 and / or BCL-xL (Borner et al. 1999; Berrieman et al. 2005), and more than 
50 % express high levels of MCL-1 (Wesarg et al. 2007; Borner et al. 1999; Zhang 
et al. 2011). 
The finding that several cancer treatments converge at the integrity of the 
mitochondrial membrane, which is regulated by BCL-2 family members, provides 
the biological rationale for targeting this family and several compounds have been 
described in the last years. The most promising strategy implies BH3-mimetics 
and several drugs have been tested (pre-)clinically as single agents or in 
combination with conventional therapy (reviewed in Lessene et al. 2008).  
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2.3.6 BCL-2 family and DNA repair 
Besides their unquestionable function in apoptosis regulation, there is emerging 
evidence that BCL-2 family members might have additional, non-canonical 
functions including impact on mitochondrial dynamics and energetics, regulation of 
transcription factor activities, cell cycle regulation, regulation of autophagy, calcium 
handling, and neuronal activity, as well as modulation of innate immunity during 
viral infections. Furthermore, some studies also predict an association of BCL-2 
family members with DNA repair pathways (reviewed in Hardwick & Soane 2013; 
Laulier & Lopez 2012), which might be interesting in regard to radiotherapy. 
Most of those studies analyzed BCL-2 itself and it was shown to inhibit all DNA 
repair systems (nucleotide excision repair (NER), base excision repair (BER), SSB 
repair, mismatch repair, DSB repair) (reviewed in Laulier & Lopez 2012). As DSBs 
are the most severe lesions after irradiation, the focus of the following section will 
be on this aspect. 
Overexpression of BCL-2 leads to unrepaired DSBs as shown by persistence of 
γH2AX foci (Wang et al. 2008) and accumulation of aberrant chromosomes 
(Kumar et al. 2010). This is, at least in part, due to nuclear accumulation of BCL-2 
and interaction with KU70, which prevents binding of Ku70 to DNA ends and 
disrupts the Ku/DNA-PKcs complex (Kumar et al. 2010; Wang et al. 2008). By this, 
BCL-2 affects effectiveness and fidelity of c-NHEJ (Wang et al. 2008; Laulier & 
Lopez 2012). However, there are also some contradictory studies, which showed 
increased c-NHEJ in the presence of BCL-2 (Sotiropoulou et al. 2010) and did not 
observe nuclear accumulation of BCL-2 (Laulier et al. 2011). BCL-2 was also 
linked to inhibition of HRR induced by various insults (Saintigny et al. 2001). 
Identification of BRCA1 as a target of BCL-2 confirmed this. BCL-2 can interact 
with BRCA1 and sequesters it in endomembranes. This in turn, leads to depletion 
of nuclear BRCA1 and a decrease in HRR (Laulier et al. 2011). Thus, BCL-2 is 
able to interfere with c-NHEJ as well as HRR. Additionally, BCL-2 can also interact 
with PARP1 and inhibit PARP1-dependent DNA repair (Dutta et al. 2012). 
BCL-xL was also linked to HRR, however, the results are contradictory in terms of 
stimulation or inhibition of repair (Saintigny et al. 2001; Wiese et al. 2002). BID and 
MCL-1 were associated with coordination of DNA damage-mediated checkpoint 
response (Jamil et al. 2008; Jamil et al. 2010; Laulier & Lopez 2012) and BAX was 
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shown to affect several repair pathways like NER, c-NHEJ, and HRR (reviewed in 
Laulier & Lopez 2012). 
In summary, the interaction between BCL-2 family members and DNA repair 
proteins seems to be complex, but it might allow very gradual responses to DNA 
damage (Laulier & Lopez 2012). 
 
 
2.4 RAF-1 
RAF-1 belongs to a protein family of serine / threonine kinases, which consists of 
three members: A-RAF, B-RAF, and RAF-1 (also known as C-RAF, c-RAF-1). This 
protein family was discovered as human homologues of the retroviral oncogene 
v-raf that was acquired by the murine retrovirus 3611-MSV (Rapp et al. 1983). In 
the same study, Rapp and colleagues also cloned RAF-1, while A-RAF as well as 
B-RAF were identified a few years later. The common structure of RAF proteins is 
made up of three conserved regions (CR1, CR2, and CR3) with an N-terminal 
regulatory domain (CR1 and CR2) and the C-terminal kinase domain (CR3) 
(Wellbrock et al. 2004). All three kinases participate in the RAS-RAF-MEK-ERK 
signal transduction pathway, which is also known as the mitogen-activated protein 
kinase (MAPK) cascade and transduces signals from cell surface to nucleus 
thereby mediating diverse biological functions (e.g. survival and differentiation) 
(Wellbrock et al. 2004). A-RAF, B-RAF as well as RAF-1 are essential for survival 
and do not have redundant functions in development as shown by genetic studies 
in mice (Mikula et al. 2001; Pritchard et al. 1996; Wojnowski et al. 1997). 
 
 
2.4.1 Regulation and function of RAF-1 
RAF-1 gets activated upon binding of extracellular ligands (e.g. growth factors, 
cytokines or hormones) to their receptors. Ligand-induced receptor stimulation 
activates the rat sarcoma (RAS) protein, which directly binds to CR1 in the N-
terminal regulatory domain of RAF (Wittinghofer & Nassar 1996). This recruits 
RAF to the plasma membrane where RAS is predominantly located (Hancock 
2003) and initiates activation of RAF in a phosphorylation-dependent manner 
(Marais et al. 1995). RAF kinases phosphorylate MEK1/2 (also known as 
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MAPK/ERK kinase), which in turn, activate ERK1/2. These effector kinases have 
more than 50 cytosolic or nuclear substrates (e.g. hypoxia-inducible factor (HIF), 
Ets-like transcription factor-1 (ELK-1), MDM2, p27kip, ARF) (Roskoski Jr. 2010; 
Gollob et al. 2006), which mainly regulate transcription, metabolism, and 
cytoskeletal rearrangements (Wellbrock et al. 2004). 
Furthermore, recent studies have demonstrated MEK/ERK-independent functions 
of RAF-1. Mice genetic studies revealed that RAF-1 directly inhibits apoptosis by 
several mechanisms that require its translocation to mitochondria (Hüser et al. 
2001; Gollob et al. 2006). This translocation can be mediated by p21-activated 
kinase (PAK)-1- or BCR-ABL-mediated phosphorylation, which then mediates 
BAD phosphorylation going along with its inactivation or BCL-2 activation (Jin et al. 
2005; Salomoni et al. 1998). Additionally, RAF-1 was shown to inhibit MCL-1 
degradation (Yoon et al. 2002). Other studies have also demonstrated that RAF-1 
inhibits the pro-apoptotic proteins ASK-1 (Chen et al. 2001; Alavi et al. 2007) and 
MST2 (O’Neill et al. 2004). All this prevents induction of the apoptosis cascade. 
Besides its effects on apoptosis, RAF-1 has also been shown to interact with ROK 
(Ehrenreiter et al. 2005) and PLK1 (Mielgo et al. 2011) in a MEK-independent 
manner, thereby driving cell migration and G2 / M cell cycle checkpoint 
progression, respectively. 
RAF kinases are regulated in a complex interplay of protein-protein interactions, 
phosphorylation as well as dephosphorylation, and conformational changes 
(Wellbrock et al. 2004) with all conserved regions contributing to this. As described 
above, CR1 mediates interaction with RAS, which promotes RAF activation. 
However, RAS does not activate RAF directly, but recruits it to the cell membrane, 
where it gets activated in a multi-step process involving dephosphorylation and 
phosphorylation (Gollob et al. 2006). CR2 mainly contributes to inhibitory 
regulation of the kinase via binding of the regulatory protein 14-3-3 in a 
phosphorylation-dependent manner (Kolch 2005). 14-3-3 binding blocks the 
interaction of RAF with RAS (Wellbrock et al. 2004). 
All RAF kinases have numerous phosphorylation sites with inhibitory as well as 
stimulatory functions (Wellbrock et al. 2004). For activation of RAF-1, the most 
important phosphorylation sites are Ser338, Ser471 as well as Tyr341 (Marais et 
al. 1995; Fabian et al. 1993; Roskoski Jr. 2010; King et al. 1998). Two additional 
phosphorylation sites within the activation segment (Thr491, Ser494) have 
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stimulatory functions (Roskoski Jr. 2010). In contrast to this, phosphorylation at 
Ser259 suppresses RAF-1 kinase activity (Roskoski Jr. 2010). 
RAF kinases dimerize to activate its kinase activity. All three family members can 
either form homo- or heterodimers (Rushworth et al. 2006) and activation occurs 
even when one monomer is kinase-dead (Roskoski Jr. 2010). 
 
 
2.4.2 RAF-1 and cancer 
The MAPK pathway is upregulated in approximately 30 % of all human cancers 
(Rushworth et al. 2006). Although RAF-1 has oncogenic potential and mutants 
have been shown to transform cells in vitro, RAF-1 mutations are rarely observed 
in human tumors (Gollob et al. 2006). However, several tumors demonstrate 
constitutive RAF-1 activation due to growth factor receptor overexpression, 
oncogenic mutations in receptor tyrosine kinases (RTK) or oncogenic RAS 
mutations, which are some of the most frequently detected genetic aberrations in 
human cancers (Downward 2003). All this is associated with onset and 
progression of tumors, like metastatic spread and therapy resistance (Gollob et al. 
2006). Several strategies of targeting the MAPK-pathway via RAF-1 have been 
developed, including antisense oligonucleotides, RAF destabilizers, and small-
molecule inhibitors (Gollob et al. 2006) and are currently under (pre-)clinical 
investigations.  
 
 
2.4.3 RAF-1 and irradiation 
The first reports on the impact of RAF-1 on radiotherapy response revealed 
contradictory results. While Kasid and colleagues demonstrated RAF-1-mediated 
radioresistance in several studies (Kasid et al. 1987; Kasid et al. 1989; Kasid et al. 
1996), Warenius et al. rather showed that RAF-1 is associated with radiosensitivity 
(Warenius et al. 1994; Warenius et al. 1996; Warenius et al. 1998). The authors 
argue that the proto-oncogene and the activated oncogene may have different 
effects on radiosensitivity. 
Later, other groups confirmed radioresistance-mediating effects of RAF-1. In an 
expression study of different squamous cell carcinoma of head and neck, RAF-1 
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overexpression was associated with resistance to radiotherapy (Riva et al. 1995) 
and furthermore, Grana et al. showed that RAF-1 contributes to RAS-mediated 
radioresistance (Grana et al. 2002). Some studies suggest targeting of RAF-1 for 
radiosensitization of human tumors (Pirollo et al. 1997; Kasid & Dritschilo 2003) 
and in the first phase I clinical trial this was also tested to be effective (Dritschilo et 
al. 2006). Here, a liposome-encapsulated RAF-1 anti-sense oligonucleotide 
(LErafAON) was used and tumor response was evaluated at completion of 
treatment. Four patients showed partial response and another four showed stable 
disease. However, four patients also experienced progressive disease. 
Furthermore, the authors claim that the liposomal composition has to be modified 
for future clinical trials, as there were dose-dependent and infusion-related 
reactions observed (Dritschilo et al. 2006). 
In summary, RAF-1 has been associated with radioresistance, but the underlying 
mechanisms remain to be elucidated although MEK-independent mechanisms are 
already proposed to be responsible (Grana et al. 2002). 
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3 Aim of the study 
Radiotherapy is an important modality in curative treatment of localized as well as 
locally advanced NSCLC and in palliative care. Simultaneous administration of 
radiation with cisplatin-based chemotherapy has moderately but consistently 
increased the curative potential of radiotherapy in locally advanced NSCLC. 
Recent improvements in treatment of metastatic NSCLC were achieved by taking 
the specific tumor biology into consideration. For example, molecularly targeted 
agents can be superior to cisplatin-based chemotherapy when patients are 
selected by genomic biomarkers detected in tumor tissues. 
Radiotherapy still does not take advantage of biological disease heterogeneity, 
although the radiotherapy response of lung cancers is dramatically varying in the 
clinic and this might be, at least in part, due to molecular differences within the 
tumors. Against this background, it was hypothesized that combining radiation with 
biomarker-stratified targeted therapy could lead to better outcomes in curatively 
intended radiotherapy protocols. A better molecular understanding of targetable 
mechanisms of radiation resistance is a prerequisite for implementation of this 
strategy. An improved understanding of the modulation of the radiotherapy 
response by signal transduction pathways may open new avenues for the 
development of more specific therapy protocols combining targeted 
pharmacotherapies with radiotherapy to improve overall treatment efficacy in lung 
cancer. Thus, the overarching aim of this study was to identify potential 
modulators of the radiotherapy response in NSCLC. 
To this end, the impact of selected regulators of apoptosis, oncogenes, and signal 
transduction mediators on irradiation-induced cell death was assessed. 
Candidates with the most striking effect (BCL-xL and RAF-1) were applied to 
further systematical experiments to validate them as modulators in vitro as well as 
in vivo and to characterize the underlying mechanisms. Additionally, targeting of 
the modulators was tested to provide the in vitro basis for the development of new 
personalized treatment protocols. 
 
 
  
 
4 Methods 
 
  
37 
4 Methods 
4.1 Cell culture methods 
4.1.1 General cell line maintenance 
Cells were cultured in medium containing 10 % fetal bovine serum (FBS, 
Biochrom), 1 % L-Glutamine (Gibco), and 1 % penicillin-streptomycin (Gibco) at 
37 °C and 5 % CO2. A431, FNX, and HEK293T cells were grown in Dulbecco’s 
modified eagle medium (DMEM, Gibco), A549 as well as H1299 cells were 
maintained in Roswell Park Memorial Institute (RPMI) 1640 medium (Gibco). 
Cells stably expressing different transgenes were generated by retroviral 
transduction (see 4.3.1; 4.3.3). Stable knockdown of specific genes was achieved 
by lentiviral transduction (see 4.3.2, 4.3.3). All stably transduced cell lines were 
maintained in the same growth medium as parental cells supplemented with 
0.5 - 1 µg/ml puromycin (Calbiochem). 
Cells were passaged twice or thrice weekly at a confluency of about 80 %. After 
washing once with Dulbecco’s phosphate-buffered saline (DPBS, Gibco), cells 
were detached using Trypsin-Ethylenediaminetetraacetic acid (Trypsin-EDTA, 
Gibco) and seeded in fresh culture medium according to their individual growth 
rate. Cells were discarded after approximately 20 - 30 passages. 
For a list of used cell lines see 8.2.1. 
 
 
4.1.2 Freezing and thawing 
For long term storage, cells were frozen in DMEM or RMPI 1640 supplemented 
with 25 % FBS and 7.5 % dimethyl sulfoxide (DMSO, Sigma-Aldrich) and stored 
at -80 °C or in liquid nitrogen. Frozen stocks were thawed in warm medium and 
centrifuged at 1,400 rpm for 5 min to remove DMSO. Supernatant was discarded 
and cells were cultured under standard conditions as described above. After 
thawing, cells were passaged at least two times before using them in experiments. 
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4.1.3 Cell counting 
For all experiments, defined numbers of cells were seeded. For counting, cells 
were collected and resuspended in fresh culture medium. Cells were diluted 1:1 in 
0.4 % Trypan blue (Invitrogen) to distinguish between dead (Trypan blue positive) 
and viable (Trypan blue negative) cells. Cell dilutions were applied to a Coun-
tessTM Cell Counting Chamber Slide (Invitrogen) and counted with a CountessTM 
Automated Cell Counter (Invitrogen). Only viable cell counts were used for 
calculation of cell numbers for seeding. 
 
4.1.4 Induction of transgene activity 
Some transgenes, namely AKT-ERtam and ΔRAF1-ERtam, were established as 
conditionally activatable systems (see 5.1). Those kinases were activated by 
adding 100 nM 4-hydroxytamoxifen (4OHT, Sigma-Aldrich) to the cell culture 
medium. 
 
 
4.2 Plasmid DNA purification 
For plasmid DNA purification, Escherichia coli (E. coli) bacteria of a glycerol stock 
were inoculated in 8 mL Circlegrow ® medium (MP Biomedicals) containing the 
suitable selective antibiotic and cultured at 32 °C and 200 rpm overnight. To 
increase bacterial yield, precultured bacteria were further grown in 140 mL 
Circlegrow ® medium supplemented with the suitable antibiotic under the same 
conditions. 
Bacteria were pelleted by centrifugation at 6,000 x g for 10 min at 4 °C and 
supernatant was discarded completely. Plasmid DNA was purified using Plasmid 
Plus Maxi Kit (QIAGEN) according to the manufacturer’s protocol. DNA was 
reconstituted in an appropriate volume of sterile Aqua destillatum (A. dest.) and 
plasmid yield was determined photometrically using a NanoDrop lite 
spectrophotometer (Thermo Scientific). 
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4.3 Establishment of stably transduced cells 
In order to assess the impact of knockdown, overexpression or activation of 
different transgenes on the radiotherapy response of various cell lines, stably 
expressing cell lines were established by retro- or lentiviral transduction. First, 
retro- or lentiviral particles were generated. Second, parental target cells were 
transduced with those particles and third, cells that expressed transgenes were 
selected by maintaining them in appropriate selection medium. 
 
 
4.3.1 Production of retroviral particles 
All transgenes that were used for overexpression or conditional activation were 
established in retroviral vectors. Therefore, retroviral particles were generated to 
stably express those transgenes subsequently in target cells. 
For the production of retroviral particles, FNX packaging cells were transfected 
with retroviral packaging plasmids and the plasmid of interest by a calcium-
phosphate transfection method (see 8.2.3 for a list of plasmids). Transfection was 
performed 24 h after seeding. A total of 13 µg DNA (10 µg plasmid of interest, 
1.5 µg polymerase plasmid, and 1.5 µg envelope plasmid) were diluted in 200 µl 
A. dest. and mixed with 50 µl CaCl2 (2.5 M). After adding 250 µl 2x HBS buffer 
(see 8.2.11) while vortexing, the mix was incubated for 5 min at RT and added 
drop-wise to the packaging cells. 6 to 16 h after transfection, culture medium was 
changed to enhance cell viability and to avoid carryover of plasmid. Virus 
containing supernatants were collected at 48 h after transfection. To avoid carry-
over of cells into the viral preparation, supernatants were centrifuged at 1,400 rpm 
for 5 min and filtered through a Minisart ® 0.2 µm filter (Sartorius Stedim Biotech). 
To monitor transfection efficiency, a control plate was always transfected with a 
green fluorescent protein (GFP) plasmid and the number of GFP positive cells was 
evaluated by flow cytometry 48 h after transfection (see 4.7.1). Viral preparations 
were either used immediately for transduction of target cells or stored in aliquots 
at -80 °C. 
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4.3.2 Production of lentiviral particles 
Stable knockdown of different genes was established by lentiviral transduction of 
target cells, as all knockdown plasmids were of lentiviral origin (see 8.2.3 for a list 
of plasmids). 
Lentiviral particles were produced by calcium-phosphate transfection of HEK293T 
cells with lentiviral packaging plasmids and the plasmid of interest. Transfection 
was conducted as for the production of retroviral particles (see 4.3.1). 
 
 
4.3.3 Transduction of target cells 
To stably express different transgenes or knockdown specific genes, parental cells 
were transduced using the retro- or lentiviral particles from sections 4.3.1 and 
4.3.2, respectively. Retro- or lentiviral particles were added to target cells 24 h 
after seeding. 6 to 8 h later, fresh medium was added and cells were further 
incubated overnight. Medium was changed 24 h after transduction. Transduction 
efficiency was controlled using an Olympus CKX41 fluorescence microscope 
(Olympus). Selection of transgene expressing cells was started 48 to 72 h after 
transduction by maintaining cells in culture medium supplemented with 1 µg/ml 
puromycin. 
 
 
4.4 Analysis of messenger ribonucleic acid (mRNA) 
expression 
In order to examine the expression of some transgenes on the level of messenger 
ribonucleic acid (mRNA), total RNA was isolated from the cells and applied to 
quantitative real-time polymerase chain reaction (qRT-PCR) after converting 
mRNA into complementary DNA (cDNA). 
 
 
4.4.1 RNA isolation and cDNA synthesis 
Total RNA was extracted using High Pure RNA Isolation Kit (Roche) according to 
the manufacturer’s protocol. RNA was eluted in 50 µL Elution Buffer. 
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Concentration and purity of extracted RNA was determined photometrically using 
a NanoDrop lite spectrophotometer (Thermo Scientific). 
cDNA synthesis was performed using Transcriptor High Fidelity cDNA Synthesis 
Kit (Roche) following the manufacturer’s guidelines. Briefly, 5 μg total RNA were 
diluted in 10.4 µL PCR grade A. dest. and mixed with 1 µl Anchored-
oligo(dT)18 Primer (final concentration 2.5 µM). For denaturation of RNA secondary 
structures, the mix was incubated at 65 °C for 10 min and subsequently cooled 
down to 4 °C. Afterwards, it was incubated with RT Mix containing Transcriptor 
High Fidelity Reverse Transcriptase Reaction Buffer, Protector RNase Inhibitor, 
Deoxynucleotide Mix, DTT, and Transcriptor High Fidelity Reverse Transcriptase 
using the following temperature protocol: 
period temperature 
30 min 50 °C 
5 min 85 °C 
∞   4 °C 
 
RNA and cDNA were stored at -20 °C. 
 
 
4.4.2 Quantitative real-time polymerase chain reaction (qRT-PCR) 
qPCR reactions were performed using the Light Cycler ® 480 SYBR Green Master 
Kit (Roche) according to the manufacturer’s protocol. Briefly, 10 µl SYBR Green I 
Master were mixed with 1 µl sense primer, 1 µl antisense primer, and 3 µl A. dest.. 
cDNA was synthesized as described in 4.4.1 and diluted 1:5 in A dest.. For each 
qPCR reaction, 5 µL cDNA dilution were applied. qPCR reactions were performed 
in triplicates on 96 well qPCR plates (Roche) using the LightCycler® 480 System 
(Roche) on basis of the following temperature protocol: 
procedure period temperature cycle 
initialization  5 min 95 °C 1 x 
denaturation 10 s 95 °C  
45 x annealing 20 s 60 °C 
elongation 30 s 72 °C 
 
melting curve 
5 s 95 °C  
1 x 60 s 65 °C 
continuous 97 °C 
cooling 10 s 40 °C 1 x 
 
The melting curve was used to analyze the specificity of the amplicon. 
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For normalization the housekeeping gene actin (P0) was used. Relative 
expression of a gene of interest (GOI) was determined as follows: 
ΔCt  = Ct (GOI) – Ct (P0) 
ΔΔCt = ΔCt (control sample) – ΔCt (treated sample) 
2ΔΔCt = relative mRNA expression 
 
qPCR primers were purchased from Eurofins MWG and are listed in 8.2.2.  
 
 
4.5 Immunoblot analysis 
Immunoblot analysis was used to control expression as well as activation of 
different transgenes and to evaluate knockdown efficiency on protein level. 
Proteins of whole cell extracts were separated by SDS-PAGE followed by 
immunoblotting. 
 
 
4.5.1 Preparation of whole cell extracts 
Cells were cultivated and treated in culture dishes as necessary. After removing 
the medium, all following steps were performed on ice to prevent protein 
degradation. Cells were washed once with cold PBS and appropriate volume of 
ice-cold NP40 lysis buffer (see 8.2.11) supplemented with cOmplete Protease 
Inhibitor Cocktail (Roche) and Phosphatase Inhibitor Cocktail 2 / 3 (Sigma-Aldrich) 
was added. After scraping cells with a Nunc® cell scraper (Thermo Scientific) and 
transferring them into a tube on ice, lysates were vortexed and incubated for at 
least 10 min on ice. To get rid of cell debris and unbroken cells, samples were 
spun down in a microcentrifuge at maximum speed (14,000 rpm) at 4 °C for 
10 min. Protein containing supernatant was transferred to a fresh tube and stored 
at -80 °C. 
 
 
4.5.2 Bradford assay to determine protein concentration 
The Bradford assay is a colorimetric assay to quantify protein concentration of a 
sample. It is based on an absorbance shift of Coomassie Brilliant Blue G250 upon 
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binding of proteins (Bradford 1976). For the measurement, 2 µl cell lysate were 
mixed with 200 µl Protein Assay Dye Reagent Concentrate (BioRad) and 800 µl 
A. dest.. Absorbance of the samples was measured against a reference (only 
Protein Assay Dye Reagent Concentrate and A. dest.) at 595 nm wavelength 
using a Gene Quant Pro spectrophotometer (GE Healthcare). Protein 
concentrations were calculated in comparison to a standard curve. 
 
 
4.5.3 SDS-PAGE 
Equal protein amounts (30 - 50 µg) were supplemented with SDS loading buffer 
(see 8.2.11) and denaturated at 95 °C for 5 min. Separation of lysates was carried 
out using the Mini-PROTEAN electrophoresis system (BioRad) for SDS-PAGE. 
10 µL PageRuler Prestained Protein Ladder (Thermo Scientific) and denaturated 
lysates were loaded and protein separation was performed at 10 mA in the 
stacking gel and 30 mA in the resolving gel. 
 
 
4.5.4 Immunoblotting 
SDS-PAGE was followed by subsequent immunoblotting. Therefore, two different 
strategies were performed: either wet blotting or semi-dry turbo blotting. For wet 
blotting, SDS-PAGE gels were blotted on Hybond ECL 0.45 µm nitrocellulose 
membranes (GE Healthcare) using the Mini-Trans Blot ® Cell tank blot system 
(BioRad). Blotting was performed at 350 mA for 70 min. For turbo blotting, SDS-
PAGE gels were blotted on nitrocellulose membranes (BioRad) using the Trans-
Blot® Turbo™ Transfer System (BioRad) according to the manufacturer’s protocol. 
Blotting was performed with the settings for 1.5 mm mini gels (1.3 A, 25 V, 
10 min). Transfer efficiency was analyzed by staining the membranes with 
Ponceau S (see 8.2.12). 
Afterwards, membranes were blocked in gelatin-containing NET-G or Blotto 
(see 8.2.12) at RT for at least 1 h and incubated with primary antibodies (see list 
8.2.4.1) at 4°C overnight. After washing thrice in NET-G or Blotto for 10 min, 
membranes were incubated with HRP-coupled secondary antibodies (see list 
8.2.4.2) for at least 1 h at RT, followed by repeated washing as described above. 
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Chemiluminescence was determined using the Super Signal West Pico system 
(Thermo Fisher Scientific) and the ChemiSmart Imaging System (Vilber Lourmat, 
France). 
 
 
4.5.5 Stripping of nitrocellulose membranes  
To analyze proteins of similar size, it was required to dehybridize nitrocellulose 
membranes from former antibodies. Therefore, the membrane was incubated in 
stripping buffer (see 8.2.11) at 55°C for 30 min. After washing thrice for 10 min and 
blocking in NET-G or Blotto for at least 1 h, membranes were again incubated with 
primary antibodies as described above (see 4.5.4). 
 
 
4.6 Irradiation 
Cells were irradiated at room temperature using a Co-60 γ-ray machine (Philips) 
with a dose rate of 0.6 - 0.9 Gy/min. For DNA repair assays, cells were irradiated 
using an X-ray machine (GE-Healthcare) operated at 320 kV, 10 mA with a 
1.6 mm aluminum filter. The dose rate was 3.6 Gy/min. 
 
 
4.7 Flow Cytometry 
Flow cytometry is a technique to analyze different cellular parameters (like cell 
size, granularity, and fluorescent staining) simultaneously on a single cell level 
within a population. This is achieved by suspending cells in a stream of fluid and 
passing them through an optical-to-electronic coupling system as single cells. The 
system detects how cells scatter incident laser light or emit fluorescence, and 
transfers this into information about the above mentioned cellular parameters. 
Here, flow cytometry was used to analyze transfection efficiency (GFP 
measurement), to examine cell cycle profiles, and to study cell death as well as 
apoptosis. 
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4.7.1 GFP measurement 
As described in 4.3, cell transfection was always accompanied by a control of GFP 
transfection to evaluate transfection efficiency. Expression of GFP in those cells 
was measured by flow cytometry. 
Cells were collected 48 h after transfection and resuspended in an appropriate 
volume of PBS. GFP expression of single cells was detected in FL1 of the FC500 
(Beckman Coulter). At least 5,000 cells per sample were analyzed. GFP 
transfected cells were compared with non-transfected cells to determine 
transfection efficiency. 
 
 
4.7.2 Cell cycle profiling and subG1 measurement 
The method to analyze cell cycle distribution by flow cytometry using propidium 
iodide (PI) staining was initially developed by Fried and colleagues (Fried et al. 
1978) and was further developed by Nicoletti and colleagues (Nicoletti et al. 1991). 
PI is a fluorescent dye, which intercalates into DNA. The method is based on 
saturated PI staining of permeabilized cells. The PI fluorescence signal is detected 
flow cytometrically and is proportional to the DNA content of each single cell. 
During the cell cycle, DNA content changes: Cells in G0/G1 phase have a diploid 
set of chromosomes (2n). After replication (S phase), chromosomes are doubled 
and cells in G2 phase have twice as much DNA (4n) as G1 cells. Therewith, 
detecting DNA content by measuring fluorescence intensity allows to distinguish 
cells in different phases of the cell cycle (Figure 7). Furthermore, this method also 
allows measuring apoptotic cells (Nicoletti et al. 1991) as DNA is extensively 
fragmented into oliginucleosomal subunits during apoptosis (Wyllie et al. 1980). 
Therewith, apoptotic cells have a hypodiploid DNA content (subG1). 
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Figure 7: Representative image of cell cycle profile. Histogram is derived from flow cytometry 
measurement. Gates indicate different cell cycle phases (G1, S, and G2/M) and apoptotic cells (subG1). 
 
For cell cycle and subG1 analysis, adherent cells as well as supernatants were 
collected at different time points after irradiation with γ-rays. Cells were incubated 
with HFS buffer (see 8.2.11) at 4 °C in the dark for at least 30 min to fix, 
permeabilize, and stain them with PI. Cell cycle distribution and subG1 content 
were analyzed by flow cytometry using FL3 of the FC500 (Beckman Coulter). For 
each sample, at least 5,000 cells were counted while doublets were excluded from 
analysis. 
 
 
4.7.3 Cell death analysis by PI exclusion assay 
To analyze cell viability, cells were stained with PI without fixing and 
permeabilizing them. Thus, PI can only enter dying cells as those lose integrity of 
the cell membrane. Therefore, only dead cells get stained with PI. 
Cells were irradiated with different doses of γ-rays and incubated for 24 - 72 h. At 
different time points, adherent cells and supernatants were collected and stained 
with 0.5 µg/ml PI (Fluka, Sigma-Aldrich) on ice for 10 min. To determine the 
portion of dead cells, PI-positive cells were quantified by flow cytometry using FL2 
of the FC500 (Beckman Coulter). The gate for PI-positive cells was adjusted to 
non-irradiated control cells and at least 5,000 cells per sample were counted. 
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4.7.4 Apoptosis analysis 
Apoptosis is characterized by certain morphologic and molecular changes of cells. 
Loss of plasma membrane asymmetry is one of the earliest features in apoptotic 
cells. In viable cells, the phospholipid phosphatidylserine (PS) is only located at 
the inner leaflet of the plasma membrane. In apoptotic cells, PS is translocated to 
the outer leaflet (Fadok et al. 1992; Martin et al. 1995). This so-called flip is used 
here to follow apoptosis by flow cytometry. Cells were stained with FITC-
conjugated Annexin V and PI. Annexin V is a phospholipid-binding protein with 
high affinity for PS and PI intercalates with DNA, but can only enter cells without 
intact membranes. The co-staining allows distinguishing between viable cells, 
early apoptotic cells, and late apoptotic / necrotic cells (Vermes et al. 1995). Viable 
cells exclude PI as well as FITC Annexin V, and represent as double negative 
(Annexin V-, PI-). Early apoptotic cells also have an impermeable membrane, 
however, they present PS on the cell surface and Annexin V can bind to it. 
Therewith, early apoptotic cells only stain for Annexin V (Annexin V+, PI-). 
Membranes of damaged or dead cells are permeable for PI and Annexin V, which 
leads to double positive stainings (Annexin V+, PI+). Following this method with 
time kinetics allows considering whether cells die via apoptosis or another mode of 
cell death. 
At different time points after irradiation with γ-rays, apoptosis was analyzed using 
the FITC Annexin V Apoptosis Detection Kit (BD Biosciences) according to the 
manufacturer’s guidelines. Briefly, cells were collected and stained with 
FITC Annexin V and PI in Annexin V Binding Buffer in the dark for 15 min. After 
diluting samples with additional Annexin V Binding Buffer, samples were kept on 
ice and analyzed by dual color flow cytometry using the FC500 (Beckman 
Coulter). FITC Annexin V was measured in FL1, PI was measured in FL3. At least, 
5,000 cells per sample were counted. Cells stained for either FITC Annexin V only 
or PI only were used for compensation of fluorescence signals. Gates were 
adjusted to non-stained and non-irradiated controls. 
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4.8 MTT assay 
Cell viability was measured with MTT assay, which is based on the cellular 
conversion of yellow tetrazolium salt 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide (MTT) to blue formazan crystals in metabolically 
active, viable cells. Thus, the amount of produced formazan is directly proportional 
to the number of viable cells. 
Appropriate numbers of cells were seeded in 96-well plates and treated with 
different substances. After indicated incubation, 10 µl of 0.5 % MTT solution (in 
PBS) were added per well and cells were incubated under standard conditions for 
additional 4 h. Cells were lyzed with 100 µl MTT solubilization buffer (see 8.2.11) 
overnight. The absorption of solubilized formazan crystals was measured with a 
spectrophotometer plate reader at 570 nm wavelength. 
 
 
4.9 Clonogenic survival assay 
The clonogenic survival assay is one of the most important assays to determine 
cellular radiosensitivity. It is based on the ability of a single cell to form a colony 
(at least 50 cells) due to unlimited cell division potential. 
For clonogenic survival assay, appropriate numbers of cells were seeded in 
60 mm petri dishes or 6-well plates allowing accurate counting of resulting 
colonies (about 100 colonies per dish / well). After 5 h, cells were irradiated with 
different doses and colonies were grown for 10 – 12 days, fixed with 70 % ethanol, 
and stained with colony staining solution (8.2.12). Colonies of more than 50 cells 
were counted. For each cell line in each experiment, the plating efficiency of non-
irradiated control cells was calculated and used to normalize survival fractions of 
irradiated cells. 
 
 
4.10 Analysis of DNA double-strand break repair 
DNA double-strand breaks (DSBs) are the most severe lesions induced by 
irradiation and repair of those breaks is required for cell survival (see 2.2.2). 
Different techniques are available to analyze presence and repair of DSBs. On a 
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physical level, DSBs were analyzed by pulsed-field gel electrophoreses (PFGE). 
Furthermore, RAD51 foci formation and dissolution were examined to study DSBs 
on a biochemical level and metaphase analyses were included to evaluate 
chromosomal aberrations induced by DSBs. 
 
 
4.10.1 Pulsed-field gel electrophoresis (PFGE) 
The accumulation of DSBs leads to fragmentation of chromosomal DNA. This 
fragmentation can be detected by pulsed-field gel electrophoresis (PFGE). Here, 
asymmetric field inversion gel electrophoresis, a subtype of PFGE, was used. It 
was developed by Stamato and Denko in 1990 (Stamato & Denko 1990) and takes 
advantage of different mobility of intact and fragmented chromosomal DNA. 
Whereas, intact chromosomes are unable to move in an agarose gel due to their 
high molecular weight, fragmented DNA is able to move. The amount of DNA that 
moves from the well into the gel is linear to the fragmentation and therewith 
depends on the applied dose. In each PFGE experiment, dose response analyses 
were performed in parallel to repair kinetics. Dose response analyses were 
necessary to examine the induction of DSBs upon irradiation with different doses 
and facilitated the comparison of results obtained from different cell lines and 
different experiments. 
For dose response analyses, cells were collected from 60 mm petri dishes after 
growing in these for two days. Cells originated from the same cell population as for 
repair kinetics. 3x106 cells/ml were embedded in serum-free growth medium 
containing 0.5 % Low Melting Agarose (Roth) and pipetted into glass tubes with 
3 mm diameter. After solidification on ice, cell-agarose suspension was extruded 
from the glass tubes and cut into 5 mm pieces (plugs). Plugs were irradiated with 
different X-ray doses (0, 5, 10, 15, 20 Gy) on ice and directly transferred to cold 
PFGE lysis buffer (see 8.2.13) in order to prohibit any repair of DSBs. Plugs were 
kept at 4 °C for 0.5 – 2 h. Hot lysis, washing and gel electrophoresis was 
performed in conjunction with repair kinetic plugs (see below). 
For repair kinetics, cells were grown in 60 mm petri dishes for two days and 
irradiated with 20 Gy of X-rays. Pre-treatment with 10 µM NU7441 was performed 
1 h before irradiation. Cells were collected at different time points and embedded 
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in serum-free growth medium containing 0.5 % Low Melting Agarose as described 
above. Cells were lysed in PFGE lysis buffer at 50 °C for 18 h. Then, agarose 
plugs were transferred to PFGE washing buffer (see 8.2.13) and incubated at 4 °C 
overnight. Afterwards, plugs were treated with washing buffer containing 0.1 mg/ml 
RNAse A (Sigma-Aldrich) at 37 °C for 1 h. 
Gel electrophoresis was carried out in 0.5 % gels of SeaKem LE Agarose (Lonza) 
supplemented with 0.5 µg/ml ethidium bromide (Roth). Gels were run in 0.5x TBE 
(see 8.2.13) at 6 °C for 40 h with alternating cycles of 50 V for 900 s in forward 
direction and 200 V for 75 s in reverse direction. Gels were scanned using a 
Typhoon 9410 Imager (GE-Healthcare). 
The fraction of DNA released (FDR) from the well into the lane, which reflects the 
amount of DSBs, was analyzed with Image-Quant (GE-Healthcare) (see Figure 
8 A). FDR of non-irradiated controls was subtracted from FDR of irradiated 
samples. In order to compare results of different cell lines and different repair 
kinetic experiments, a dose response curve was generated by plotting FDR of 
samples that have been irradiated with different doses against the applied 
radiation dose. Dose response curves were used to calculate dose equivalents 
(DEQ) from each FDR value of the repair kinetics (Figure 8 B, dotted lines). DEQ 
was plotted against time and repair kinetic curves were fitted using non-linear 
regression analysis of SigmaPlot software (Version 13, Systat Software Inc). 
 
 
Figure 8: Representative dose response curve of PFGE. (A) Image of ethidium bromide stained gel. 
Fraction of DNA released (FDR) from the well into the lane (regions as indicated) was analyzed to plot a dose 
response curve (B). Dotted lines indicate the approach that was used to calculate DEQ from FDR for repair 
kinetics. 
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4.10.2 RAD51 foci formation and dissolution 
RAD51 is an important component of HRR (see 2.2.2.1) and can be detected with 
a confocal microscope as foci upon immunofluorescent staining. Thus, RAD51 foci 
do not only give information about the presence of DSBs, but also indicates the 
used repair pathway. Formation and dissolution of RAD51 foci upon irradiation 
was analyzed by immunofluorescence stainings followed by fluorescence 
microscopy. 
Cells were grown on glass coverslips (20 mm diameter, VWR) for two days and 
irradiated with 4 Gy of X-rays. At different time points after irradiation, cells were 
fixed with 2 % paraformaldehyde/PBS (Roth) for 15 min at RT. After washing with 
PBS, permeabilization was performed by incubating coverslips in P-solution 
(see 8.2.14) at RT for 7 min. Coverslips were washed with PBS and blocked with 
PBG (see 8.2.14) either at RT for 1.5 h or at 4 °C overnight. For immunostaining, 
primary antibodies (see list 8.2.4.3) were diluted in PBG and incubated at RT for 
1 h. After washing thrice with PBS at RT for 5 min, coverslips were incubated with 
fluorophore-coupled secondary antibodies (see list 8.2.4.4) diluted in PBG at RT in 
the dark for 1 h. After washing thrice with PBS for 5 min (in the dark), cells were 
stained with 50 ng/ml DAPI for 10 min and mounted with PromoFluor Antifade 
reagent (PromoKine) in the dark at RT overnight. Microscopy was performed on a 
Leica DMR fluorescence microscope. Pictures were taken with a QuantiFire XI 
camera (Intas) using LAS AF software (Leica Microsystems) and analyzed with 
Imaris 8.0.2 (Bitplane). 
 
 
4.10.3 Analysis of metaphases 
Molecular DNA lesions, particularly DSBs, may lead to chromosomal changes 
(e.g. chromatid breaks, translocations). Visualizing chromosomes in metaphase 
facilitates analysis of chromosomal aberrations upon irradiation. 
Metaphase preparation was performed as described previously (Bryant et al. 
2008). Exponentially growing cells were irradiated with 1 Gy of X-rays and were 
allowed to repair for 8 – 20 h at 37 °C. To accumulate cells at metaphase, 
0.1 µg/ml colcemid (L-6221, Biochrom) was added 1 h before collecting the cells. 
At each time point, cells were collected and treated with hypotonic solution 
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(see 8.2.15) at RT for 10 min. After centrifugation with 1,000 rpm at 4 °C for 7 min, 
supernatant was discarded and cells were fixed with Carnoy’s fixative (see 8.2.15) 
at 4 °C overnight. Before dropping cells on clean glass slides (Roth), fixed cells 
were washed 4 times with Carnoy’s fixative. Chromosomes were stained with 3 % 
Giemsa (Roth) in Sorenson’s buffer (Gibco, life technologies) and mounted with 
coverslips (Roth) using Entellan® (Merck). Images of metaphases were taken 
using an Olympus Vanix-T bright field microscope with an AVT Vimba Marlin 
F046B camera. For each experimental point, 50 – 100 metaphases were analyzed 
in terms of chromatid breaks, dicentrics, sister unions, chromosomal 
translocations, and acentric fragments (see Figure 24 A). 
 
 
4.11 Mouse xenografts 
In order to validate modulators of the radiotherapy response in vivo, tumor 
xenografts were established in non-obese diabetic severe combined 
immunodeficiency (NOD/SCID) mice, followed by local tumor irradiation and 
analysis of tumor growth. Mice were sacrificed, when tumors reached 1.5 mm 
diameter or when general conditions declined. All animal studies were conducted 
in compliance with institutional guidelines and German Animal Protection Law, and 
were approved by the responsible regulatory authority (Landesamt für Natur, 
Umwelt und Ver-braucherschutz Nordrhein-Westfalen, Az. G1399/13). 
 
 
4.11.1 Injection of tumor cells 
1x106 exponentially growing cells were suspended in 50 µl matrigel (growth factor 
reduced, Corning) and injected subcutaneously into the right hind limb of 
NOD/SCID mice (Charles River Laboratories). 
 
 
4.11.2 Induction of transgenes 
In order to induce transgene activation in xenografts of A431 [AKT-ERtam] or 
A431 [ΔRAF1-ERtam], feeding of mice with Tamoxifen Diet (400 mg/kg, irradiated, 
Harlan) started four days after injection of cells. 
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4.11.3 Local tumor irradiation 
When tumors reached about 0.3 to 0.6 mm in diameter, tumor-bearing limbs were 
irradiated with a local, single dose of 4 Gy using a Co-60 γ-ray machine (Philips) 
while the total body was shielded. 
 
 
4.11.4 Measurement of tumor growth 
Tumor size was measured with an Electronic Digital Caliper (VWRI819-0013, 
Control Company) in two diameters thrice a week and calculated by multiplying 
width and length. As tumors differed in size at the time of irradiation, relative size 
was calculated for each time point using the day before irradiation as reference. 
The relative impact of irradiation on tumor growth was calculated as follows: 
 mean of relative size non-irradiated – mean relative size irradiated 
 
 
4.11.5 Protein extracts from tumor tissues 
To validate expression and activation of transgenes within tumor tissue, 
subcutaneous tumors were carefully dissected from skin and surrounding tissue, 
placed in a tube with NP40 lysis buffer supplemented with inhibitors (see 8.2.11), 
and cut with a scissors. After vortexing and incubating for at least 15 min on ice, 
tumor tissue was homogenized using the MagNA Lyser Instrument (Roche) at 
7,000 min-1 for 5 s. Homogenates were further incubated on ice for 10 min and 
centrifuged at 14,000 rpm and 4 °C for 10 min. Protein-containing supernatants 
were stored at -80 °C. Before measuring protein concentration (compare 4.5.2), 
lysates were centrifuged again at 14,000 rpm and 4 °C for 30 min. 
 
 
4.12 Data evaluation 
Cell culture experiments were repeated up to three times, if not other stated. 
Analysis and graphing was done using GraphPad Prism (Version 6). For statistical 
analysis, unpaired t-test or Two-Way ANOVA were applied. 
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5 Results 
The central aim of this project was to identify and characterize modulators of the 
radiotherapy response of NSCLC in vitro and in vivo. To this end, the functional 
impact of selected regulators of apoptosis, oncogenes, and signal transduction 
mediators on irradiation-induced cell death, clonogenic survival, cell cycle 
regulation as well as DNA repair was evaluated. Starting with a small-scale in vitro 
screen (see 5.1) to identify potential modulators, two paradigms were further 
characterized: members of the BCL-2 family (see 5.2) and the signal transduction 
mediator RAF-1 (see 5.3). 
 
 
5.1 Identification of potential modulators of the radiotherapy 
response in vitro 
In order to identify potential modulators of the radiotherapy response, a small-
scale screen of selected modulator candidates was performed in vitro. For 
candidate selection, a literature study of candidates mediating resistance against 
other treatment modalities was conducted. Several groups discovered that 
resistance to DNA-damaging drugs and targeted therapies is often caused by 
functional defects in the apoptotic machinery (Wesarg et al. 2007; Meiler et al. 
2012; Kasper, Breitenbuecher, Heidel, et al. 2012; Kutuk & Letai 2008). The same 
mechanism also influenced the outcome of antibody-based therapies and 
immunotherapies (Stolz et al. 2008; Huber et al. 2005; Ravi et al. 2006). Besides 
this, oncogenes and deregulation of growth factor signaling impeded with the 
success of cancer therapy in vitro (Kasper, Breitenbuecher, Reis, et al. 2012; 
Hähnel et al. 2008; Mok et al. 2009; Pogorzelski et al. 2014). Based on this, the 
following clinically relevant candidates were selected to determine their effect on 
radiation modulation: 
- regulator of cell death: BCL-xL 
- mediators of growth factor signaling: AKT, K-RASwt, RAF-1 
- oncogenes: K-RASG12V, E6, E7 
The small-scale screen was performed using A431 cells, which originate from an 
epidermoid carcinoma (Giard et al. 1973) and are often used as a model for lung 
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cancer due to their high expression of the epidermal growth factor receptor 
(EGFR). A431 cells stably expressing BCL-xL, K-RASwt, K-RASG12V, E6 or E7 
were established by retroviral transduction, which allowed constitutive 
overexpression of these transgenes. Additionally, A431 cells were transduced with 
AKT-ERtam or ΔRAF-1-ERtam expression vectors to induce AKT or RAF-1 activity 
pharmacologically in those cells. 
AKT-ERtam is a fusion product of a constitutively active variant of AKT and a 
mutant hormone-binding domain of the murine estrogen receptor (ER) 
(Kohn et al. 1998; Hähnel et al. 2008) (Figure 9 A, left). The constitutively active 
variant of AKT lacks its PH domain, which mediates protein-lipid or protein-protein 
interactions (Haslam et al. 1993; Mayer et al. 1993), but contains a src 
myristoylation signal that targets AKT to membranes and causes AKT activation 
by an increase in phosphorylation (Kohn et al. 1996). The mutant hormone-binding 
domain of the murine ER is transcriptionally inactive and unable to bind estrogen 
(17β-estradiol), but retains normal affinity for the synthetic ligand 
4-hydroxytamoxifen (4OHT) (Littlewood et al. 1995). In this fusion construct, 
kinase activity depends on the addition of exogenous 4OHT. In the absence of 
4OHT, the fusion protein is kept in an inactive state due to a conformation that 
masks the myristoylation signal. In the presence of 4OHT, the fusion protein 
undergoes a conformational change, which unmasks the myristoylation signal, and 
therefore, allows integration of AKT into a membrane compartment that leads to its 
activation by phosphorylation (Figure 9 B, left). 
RAF-1 consists of an N-terminal regulatory domain including region CR1, which is 
necessary for RAS-binding (Nassar et al. 1995), and region CR2, which contains 
several regulatory sites (Morrison et al. 1993). This regulatory domain functions to 
suppress the catalytic activity of the kinase, which is located at the C-terminus in 
region CR3 (Figure 9 A, right). In the ΔRAF-1-ERtam fusion protein, RAF-1 lacks 
the regulatory domain, which leads to a constitutively active kinase (Balmanno et 
al. 2003; Stanton Jr. et al. 1989). For inducible control of the kinase, ΔRAF-1 is 
fused to the mutant hormone-binding domain of the murine ER mentioned above 
(Littlewood et al. 1995). In the absence of 4OHT, ER mimics the regulatory domain 
of RAF-1 and keeps the kinase inactive by conformational features. In the 
presence of 4OHT, the fusion protein undergoes a conformational change, which 
promotes kinase activation by phosphorylation, which is possibly maintained by 
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either interaction with other proteins or by homodimerization-induced auto- or 
trans-phosphorylation (Figure 9 B, right). 
 
 
Figure 9: Activation mechanism of conditionally activatable transgenes. (A) Schematic drawing of 
AKT-ERtam construct modified from Kohn et al. 1998 (left) and ΔRAF1-ERtam (right). (B) Mechanism of 
activation of AKT-ERtam (left) and ΔRAF1-ERtam (right) upon treatment with 4-hydroxytamoxifen (4OHT). The 
asterisk indicates active kinases. 
 
Expressions of K-RASwt, K-RASG12V, and BCL-xL as well as conditional activation 
of AKT-ERtam and ΔRAF-1-ERtam in A431 cells stably transduced with the 
corresponding vectors were validated by immunoblotting (Figure 10). Activation of 
AKT and RAF-1 in the presence of 4OHT was stable for at least 68 h (Figure 
10 C, D). E6 and E7 expression in stably transduced A431 cells was confirmed by 
qPCR, as antibodies for those proteins were not available (Figure 10 E). 
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Figure 10: Validation of transgene expression and activation. (A, B) Expression of K-RASwt, 
K-RASG12V (A) and BCL-xL (B) in A431 cells stably transduced with the corresponding pBabe-Puro expression 
vectors compared to parental cells (P). Protein levels were evaluated by immunoblotting, actin served as a 
loading control. (C, D) Kinetics of AKT-ERtam (C) or ΔRAF-1-ERtam (D) activation in A431 cells stably 
transduced with the corresponding expression vectors and treated with 100 nM 4OHT for indicated time 
intervals. Protein levels of phosphorylated AKT (Ser473) and total AKT or RAF1 (Ser338) or total RAF1 were 
evaluated by immunoblotting. Actin served as a loading control. (E) Relative expression of HPV E6 and E7 
mRNA in A431 cells stably transduced with the corresponding expression vectors. mRNA levels were 
measured by qPCR after transcription into cDNA. 
 
In the small-scale screen, all transgenes were initially tested for their impact on 
radiation-induced cell death. To this end, cells were treated with different doses of 
γ-irradiation (0, 2, 6, 10 Gy) at 20 h after seeding and inducing kinase activity. Cell 
death was determined by PI exclusion assay at different time points after 
irradiation (48 and 72 h). The induction of cell death upon irradiation was dose 
  
 
5 Results 
 
  
58 
dependent and increased from 48 to 72 h (Figure S 1, Figure 11). All selected 
transgenes, except for AKT, mediated a significant decrease of irradiation-induced 
cell death compared to control cells, either parental A431 cells or A431 cells stably 
transduced with an empty vector control (Figure 11). BCL-xL and RAF-1 showed 
the strongest effects. As BCL-xL was already known to confer resistance to other 
treatment modalities and has strong clinical relevance (compare 2.3.5), the 
following studies were focused on this protein and its other family members (see 
5.2). Furthermore, some initial experiments were also performed to further 
characterize the impact of RAF-1 (see 5.3) on the radiotherapy response. 
 
 
Figure 11: Impact of different transgenes on irradiation-induced cell death. A431 cells stably expressing 
indicated transgenes were stained with PI 72 h after irradiation with indicated doses (0 – 10 Gy) and the 
fraction of PI-positive cells was determined by flow cytometry (mean + SD, n=3). * p ≤0.05, ** p ≤0.01, 
*** p ≤0.001 (compared to parental or vector control cells). 
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5.2 Characterization of BCL-2 family members as modulators 
of radiotherapy response 
As shown above, BCL-xL mediated the strongest resistance effect against 
irradiation evaluated by determining cell death in short-term experiments. 
Therefore, the impact of the BCL-2 family, which BCL-xL is a member of, on the 
radiotherapy response of NSCLC models was further characterized. 
 
 
5.2.1 Long-term survival after irradiation in the presence of BCL-xL 
overexpression 
Two different approaches were followed to examine whether BCL-xL also has an 
impact on long-term survival after irradiation. In the first approach, equal numbers 
of A431 cells, either parental or with constitutive BCL-xL overexpression, were 
seeded, irradiated with increasing doses of γ-irradiation (0 – 10 Gy), and grown for 
6 – 9 d until colonies were visible (Figure 12 A). By this, it was visualized that the 
clonogenic survival of BCL-xL cells after irradiation was higher compared to 
parental cells. Non-irradiated parental and BCL-xL cells showed similar numbers 
and sizes of colonies, whereas in irradiated samples BCL-xL cells always 
presented more and bigger colonies. 
In the second approach, different numbers of cells were plated allowing accurate 
counting of resulting colonies to calculate survival fractions. Colonies from all 
samples were fixed and stained on the same day. Survival fractions were 
normalized to the plating efficiency of corresponding non-irradiated cells. Plotting 
survival fractions against the applied dose confirmed a survival benefit of BCL-xL 
overexpressing cells compared to parental and empty vector control cells (Figure 
12 B). 
In summary, this shows that enforced expression of BCL-xL not only mediates 
resistance against irradiation-induced cell death but also promotes long-term 
survival. 
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Figure 12: Long-term survival of A431 cells with enforced BCL-xL expression. (A) Representative 
images of colony formation of A431 cells stably transduced with BCL-xL expression vector compared to 
parental A431 cells. Equal numbers of cells were plated and irradiated with indicated doses (0 – 10 Gy). 
Images of stained colonies were taken after 6 – 9 d. (B) Clonogenic survival of A431 cells stably expressing 
BCL-xL and control cells (parental, vector control). Different numbers of cells were plated and irradiated with 
0 – 10 Gy. Colonies were stained and counted after 11 d (mean + SD, n=2). 
 
To validate the impact of BCL-xL on the radiation response in an organismal 
context in vivo, subcutaneous tumors were established by injection of A431 cells, 
expressing either BCL-xL or empty vector control, in the right hind limb of 
NOD/SCID mice. Comparing tumors with BCL-xL expression and control tumors, 
equal initial outgrowth and growth rates were observed. On day 11 after injection, 
outgrowing tumors were irradiated with a single fraction of 4 Gy local dose while 
the total body was shielded. At this time point, tumors had reached 0.3 to 0.6 cm in 
diameter. Due to this diversity in tumor size at the time of irradiation, relative tumor 
growth was calculated and compared between BCL-xL overexpressing tumors and 
control tumors. Interestingly, the impact of irradiation on relative tumor growth was 
higher in control xenografts compared to BCL-xL expressing xenografts (Figure 
13). 
This shows, that expression of BCL-xL also confers radioresistance in vivo. 
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Figure 13: Relative impact of irradiation on tumor growth of BCL-xL overexpressing xenografts 
compared to control. (A) NOD/SCID mice received subcutaneous injections of A431 cells stably transduced 
with a BCL-xL expression vector (BCL-xL) or an empty vector control (Ctrl.). After 11 days, established tumors 
were irradiated with 4 Gy. Tumor growth was measured using a caliper and the impact of irradiation on 
relative tumor growth was calculated. (B) BCL-xL expression in tumors was controlled by immunoblotting, 
actin served as a loading control. * p ≤0.05 (compared to control cells at the same time point). 
 
 
5.2.2 MCL-1-mediated radioresistance 
Next, it was asked whether other anti-apoptotic BCL-2 family members also 
mediate resistance against irradiation or whether it is a BCL-xL-specific effect. To 
rule this out, MCL-1 was analyzed. This anti-apoptotic BCL-2 family member is 
one of the most frequently amplified genes in human cancer (Beroukhim et al. 
2010; Wei et al. 2012) and is therefore of specific clinical interest. A431 cells 
stably expressing MCL-1 (Figure 14 A) were applied to short-term cell death and 
long-term clonogenic survival experiments. PI exclusion measured at 72 h post 
irradiation with 10 Gy revealed a significant decrease of PI-positive dead cells 
upon enforced expression of MCL-1 (Figure 14 B). However, compared to BCL-xL 
the effect was less pronounced. Nevertheless, MCL-1 also gave a competitive 
edge in clonogenic survival compared to control cells (Figure 14 C). 
In summary, mediation of resistance against irradiation is no specific feature of 
BCL-xL, but also other anti-apoptotic BCL-2 family members like MCL-1 show 
similar effects concerning short-term as well as long-term survival in vitro. 
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Figure 14: MCL-1-mediated resistance against irradiation. (A) Expression of MCL-1 in A431 cells stably 
transduced with a MCL-1 expression vector compared to parental cells (P). Protein levels were evaluated by 
immunoblotting, actin served as a loading control. (B) Irradiation-induced cell death of parental A431 cells, 
A431 cells stably transduced with an empty vector control (Ctrl.) and A431 cell stably transduced with a 
MCL-1 expression vector. Cells were stained with PI 72 h after irradiation with 10 Gy or sham-irradiation. The 
fraction of PI-positive cells was determined by flow cytometry (mean + SD, n = 3). (C) Long-term survival of 
MCL-1 overexpressing and control cells measured by colony formation after irradiation with different doses 
(mean + SD, n = 3). *** p ≤ 0.001 (compared to parental and vector control cells). 
 
 
5.2.3 Interference with endogenous anti-apoptotic BCL-2 family members 
to radiosensitize NSCLC cells 
The above-mentioned results demonstrate that two different anti-apoptotic BCL-2 
family members mediate resistance against irradiation in A431 cells. In the next 
step, the data should be verified in different NSCLC cell lines to exclude cell line 
specific functions of BCL-xL and MCL-1. However, several NSCLC cell lines 
showed higher intrinsic radioresistance than A431 cells (compare Figure 15), 
which rendered these cells unsuitable to validate resistance-mediating modulators. 
Thus, the data was validated by targeting endogenous anti-apoptotic BCL-2 family 
members in those cells, which should result in sensitization towards irradiation. 
Two different approaches were used to test this hypothesis: (1) short hairpin RNA 
(shRNA)-mediated knockdown of BCL-xL and MCL-1, and (2) conditional 
expression of pro-apoptotic BAK. 
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Figure 15: Resistance of NSCLC cells against irradiation. Irradiation-induced cell death of different 
NSCLC cells measured by PI staining 72 h after irradiation with 10 Gy or sham irradiation. The fraction of PI-
positive cells was determined by flow cytometry (n=1). 
 
For the first approach, stable knockdown of BCL-xL or MCL-1 was established by 
lentiviral transduction with vectors encoding shRNA from the MISSION TRC Mm 
1.0 library (BCL-xL: TRCN 0000033499 – 503, MCL-1: TRCN 0000005514 – 518; 
Sigma-Aldrich) in A549 and H1299 lung cancer cell lines as well as in A431 cells. 
Immunoblotting confirmed knockdown efficiency of five different shRNAs for each 
target (Figure 16). Regarding BCL-xL knockdown, A549 and H1299 showed 
comparable patterns, whereas A431 cells differed slightly (Figure 16 A, C, E). In all 
three cell lines clone 499 induced a very efficient knockdown and was therefore 
used for all following experiments. Knockdown of MCL-1 was in general less 
effective and differed among the three cell lines (Figure 16 B, D, F). In A549 cells, 
clone 518 showed the highest knockdown efficiency. In H1299 cells, only three 
shRNAs allowed survival of transduced cells, but compared to parental H1299 
cells none of those was really efficient in knocking MCL-1 down. Knockdown 
efficiency of clone 516 and 517 was best in A431 cells. 
 
 
 
  
 
5 Results 
 
  
64 
 
Figure 16: Expression of BCL-xL and MCL-1 in cells with knockdown. Expression of BCL-xL and MCL-1 
was evaluated by immunoblotting in indicated cells stably expressing different lentiviral shRNA expression 
vectors targeting BCL-xL or MCL-1. Protein levels were compared to parental cells (P) and cells stably 
expressing a control shRNA vector (shRNA scr.). Actin served as a loading control. (A) A549 with BCL-xL 
knockdown, (B) A549 with MCL-1 knockdown, (C) H1299 with BCL-xL knockdown, (D) H1299 with MCL-1 
knockdown, (E) A431 with BCL-xL knockdown, (F) A431 with MCL-1 knockdown. 
 
The impact of BCL-xL and MCL-1 knockdown on the radiotherapy response was 
elucidated in short-term and long-term survival assays. As expected, knockdown 
of both modulators revealed radiosensitizing effects in A549 and A431 cells: 
knockdown cells showed significantly increased radiation-induced cell death 
(Figure 17 A – D) and decreased clonogenic survival (Figure 17 E – H).  
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Figure 17: Sensitization of A549 and A431 cells to IR by knockdown of BCL-xL and MCL-1. 
(A, B) Irradiation-induced cell death of control A549 cells (parental, shRNA scr.) and BCL-xL (A) or MCL-1 (B) 
knockdown A549 cells (shRNA BCL-xL, shRNA MCL-1) 72 h after irradiation with 10 Gy or sham irradiation. 
The portion of dead cells was determined by staining with PI followed by flow cytometry (mean + SD, n = 2). 
(C, D) Irradiation-induced cell death of control A431 cells (parental, shRNA scr.) and BCL-xL (C) or MCL-1 (D) 
knockdown A431 cells (shRNA BCL-xL, shRNA MCL-1) 72 h after irradiation with 10 Gy or sham irradiation. 
Cell death was measured as in A. (E, F) Long-term survival of BCL-xL (E) or MCL-1 (F) knockdown A549 cells 
compared to control cells (shRNA scr.) measured by colony formation after irradiation with different doses 
(mean + SD, n = 3). (G, H) Long-term survival of BCL-xL (G) or MCL-1 (H) knockdown A431 cells compared 
to control cells (shRNA scr.) measured by colony formation after irradiation with different doses (mean + SD, 
n = 3). * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. 
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In H1299 cells, the radiosensitizing effect of BCL-xL knockdown was also 
confirmed, while MCL-1 knockdown was not efficient in those cells and therefore 
had no impact on short- or long-term survival (Figure 18). 
 
 
Figure 18: Sensitization of H1299 cells to IR by knockdown of BCL-xL. (A, B) Irradiation-induced cell 
death of control cells (parental, shRNA scr.) and BCL-xL (A) or MCL-1 (B) knockdown cells (shRNA BCL-xL, 
shRNA MCL-1) 72 h after irradiation with 10 Gy or sham irradiation. Cell death was determined by staining 
with PI followed by flow cytometry or determination of subgenomic DNA content (mean + SD, n = 2). 
(C, D) Long-term survival of BCL-xL (C) or MCL-1 (D) knockdown cells compared to control cells (shRNA scr.) 
measured by colony formation after irradiation with different doses (mean + SD, n = 3). *** p ≤ 0.001. 
 
The second approach of targeting endogenous anti-apoptotic BCL-2 family 
members was conditional expression of pro-apoptotic BAK in primarily 
radioresistant A549 cells. BAK belongs to the Bax-like death factors of the BCL-2 
family and is a functional antagonist of BCL-xL and MCL-1 (Chittenden et al. 1995; 
Willis et al. 2005). Conditional overexpression of BAK changes the balance 
between pro-survival proteins (like BCL-xL and MCL-1) and pro-apoptotic proteins 
(like BAK and BAX), which primes cells for dying upon death signals (Danial & 
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Korsmeyer 2004). In this system, which was established before (Wesarg et al. 
2007), addition of doxycycline (Dox) induced transcription of BAK, which led to 
increased BAK protein levels (Figure 19 A). The impact of conditional BAK 
expression on the radiotherapy response was again analyzed in short- and long-
term assays. Induction of BAK in itself was slightly toxic, however the combination 
with irradiation (10 Gy) augmented the number of PI-positive, dead cells (Figure 
19 B). More importantly, accelerated BAK expression also reduced long-term 
clonogenic survival of radioresistant A549 cells (Figure 19 C). 
 
 
Figure 19: Functional block of BCL-xL by conditional overexpression of pro-apoptotic BAK. 
(A) Validation of conditional BAK expression in A549 cells stably transduced with a tet-on BAK expression 
system. BAK expression was induced by adding 100 ng/ml doxycycline for 24 h. Expression was evaluated by 
immunoblotting and compared to non-treated tet-on BAK cells and parental cells. Actin served as a loading 
control. (B) Irradiation-induced cell death of tet-on BAK cells in the presence or absence of doxycycline. 24 h 
before irradiation with 10 Gy or sham irradiation, BAK expression was induced as in A. Cell death was 
measured 72 h after irradiation by determining the cell fraction with subgenomic DNA content using flow 
cytometry (mean + SD, n = 4). (C) Long-term survival of tet-on BAK cells in the presence or absence of 
100 ng/ml doxycycline and irradiation with indicated doses (mean + SD, n = 3). *** p ≤0.001. 
 
 
5.2.4 Mechanistic dissection of radioresistance mediated by BCL-2 family 
proteins 
Thinking about underlying mechanisms leading to resistance against irradiation 
mediated by BCL-xL and MCL-1, the obvious assumption was the inhibition of 
apoptosis, as this is the main known function of both modulators. Interestingly, 
only a minor fraction of irradiated A431 cells exhibited features of early apoptosis 
such as membrane externalization of phosphatidylserine (Figure 20). This was 
analyzed by AnnexinV-PI double stainings followed by flow cytometry at several 
time points post irradiation (4, 6.5, 24, and 48 h). Thus, those results suggested 
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that BCL-xL and MCL-1 also interfere with non-apoptotic radiation-induced death 
pathways. 
 
 
Figure 20: Analysis of apoptosis induced by irradiation. A431 cells stably expressing either vector control 
or BCL-xL vector were treated with 10 Gy or sham irradiation and stained with AnnexinV-FITC and PI at 
different time points (4, 6.5, 24 and 48 h). Early apoptotic cells (AnnexinV-positive, PI-negative) and late 
apoptotic / necrotic cells (AnnexinV-positive, PI-positive) were determined by flow cytometry. 
(A) Representative images of flow cytometry plots. X-axis: AnnexinV-FITC, y-axis: PI. (B) Quantification of 
early apoptotic (left) and late apoptotic / necrotic cells (right) plotted against time (mean + SD, n = 3). 
 
To further explore the mechanistic basis of radioresistance, cell cycle checkpoints 
and DNA repair pathways were studied in relation to expression of anti-apoptotic 
BCL-xL, as these are the major cellular responses to ionizing radiation (Ross 
1999). Irradiation induced a transient G2-arrest in A431 vector control cells and 
A431 cells with BCL-xL overexpression (Figure 21). The G2-arrest reached its 
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plateau at 8 h and was maintained until 24 h post irradiation. Cells with BCL-xL 
overexpression seemed to recover slightly faster, but this was no significant effect. 
Consequently, it was hypothesized that BCL-xL might interfere with DNA repair 
pathways. 
 
 
Figure 21: Analysis of cell cycle distribution upon irradiation. A431 cells stably expressing either vector 
control or BCL-xL vector were treated with 10 Gy or sham irradiation and cell cycle distribution was analyzed 
by flow cytometry at indicated time points (0, 4, 8, 24, and 48 h). (A) Representative images of histograms. 
(B-D) Quantification of cells in G1 phase (B), S phase (C), and G2/M phase (D after irradiation with 10 Gy 
(mean + SD, n = 3). 
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Ionizing radiation induces several DNA damages whereupon DNA DSBs are the 
principle cytotoxic lesions (Iliakis 1991). Hence, kinetics of DSB repair were 
evaluated in the presence or absence of enforced BCL-xL expression. DSBs 
accumulate upon ionizing radiation, which leads to DNA fragmentation in a dose-
dependent manner and can be visualized by pulsed-field gel electrophoreses 
(PFGE). DNA fragments migrate size-dependently in an agarose gel under the 
influence of a pulsed electric field. The higher the dose, the higher the number of 
fragments and the more DNA migrates from the well into the lane (compare Figure 
8 A). The fraction of DNA released (FDR) was quantified and plotted as a function 
of the applied radiation dose to generate dose-response curves (see Figure 22 A). 
In both cell lines, control A431 cells and BCL-xL overexpressing A431 cells, the 
increase of FDR was linear to the applied dose and equaled in both cell lines. This 
confirmed that BCL-xL has no impact on the induction of DSBs per unit of 
absorbed radiation dose. 
For DSB repair kinetics, control A431 cells and BCL-xL overexpressing cells were 
irradiated with 20 Gy and repair was measured in the time interval of 0.5 to 8 h. 
Dose equivalents (DEQ) were calculated from the FDR at each time point based 
on dose-response curves to allow a higher comparability between different 
experiments (compare Methods section 4.10.1). DEQ reflects the equivalent dose 
for remaining DSBs at each time point. In both cell lines, about 90 % of induced 
DSBs were processed with fast kinetics within 1 h. Remaining DSBs were repaired 
within 4 to 8 h (Figure 22 B). Under these conditions, c-NHEJ is the dominant 
repair pathway and only marginal differences were observed in cells expressing 
BCL-xL. 
To explore whether BCL-xL impacts on other DSB repair pathways, repair kinetic 
experiments were conducted in the presence or absence of NU7441. This small 
molecule is a highly potent and selective inhibitor of DNA-dependent protein 
kinase (DNA-PK), which is a key enzyme of c-NHEJ (compare 2.2.2.2). Under 
conditions of inhibited c-NHEJ, alt-EJ functions as backup and operates with slow 
kinetics, while HRR is not found to be involved in repair of DSBs under those 
conditions (Wang et al. 2001; Wu, Wang, Mussfeldt, et al. 2008; Wu, Wang, Wu, 
et al. 2008). As expected, inhibition of DNA-PK resulted in a slowdown of DSB 
repair compared to non-treated cells (Figure 22 C). Whereas all DSBs were 
repaired within 8 h in non-treated cells, in NU7441-treated cells about 25 % of 
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DSBs were still remaining after 8 h. Strikingly, in BCL-xL overexpressing cells 
approximately 50 % of DSBs were processed within 0.5 to 1 h, while control cells 
showed 50 % repair after 4 h. Thus, A431-BCL-xL cells tended to repair faster 
than A431-control cells, when c-NHEJ was blocked. This indicated that BCL-xL 
reduces the delay of alt-EJ repair. 
 
 
Figure 22: Analysis of DSB repair kinetics as a function of BCL-xL expression. (A) Dose response 
curves for the induction of DSBs in control A431 cells and BCL-xL overexpressing A431 cells exposed to 
different doses of IR (0 – 20 Gy) and measured by PFGE. (B) Repair kinetics of IR-induced DSBs after 
irradiation with 20 Gy. FDR at each time point after irradiation was converted to dose equivalents (DEQ) with 
the help of dose response curves, as described in the methods section (mean + SD). (C) Repair kinetics of IR-
induced DSBs in A431 control and BCL-xL overexpressing cells measured in the presence or absence of the 
DNA-PK inhibitor NU7441. Cells were pretreated with 10 µM NU7441 for 1 h prior to irradiation with 20 Gy. 
FDR of each time point was converted in DEQ using dose response curves (mean + standard error, n = 2 with 
4 samples each).  
 
To further specify whether those effects have also an impact on cellular outcome 
after irradiation, colony formation assays were performed in the presence of 
NU7441. Interestingly, inhibition of c-NHEJ indeed reduced clonogenic survival 
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after irradiation, but BCL-xL overexpressing cells still showed higher survival 
compared to control cells (Figure 23 A). 
The third repair pathway of DSBs, namely HRR, was inhibited by B02, a RAD51-
specific inhibitor. B02 markedly reduced radiation-induced RAD51 foci formation 
(Figure S 3), but colony formation assays revealed only minor contribution of HRR 
to DSB repair in this context, as clonogenic survival in the presence of B02 was 
only marginally reduced compared to non-treated cells. Interestingly, the BCL-xL-
mediated increase of clonogenic survival was abolished by treatment with B02 and 
there was no difference observable between BCL-xL overexpressing cells and 
control cells upon impaired HRR (Figure 23 B). This indicates that BCL-xL-
mediated resistance depends on HRR, at least under these experimental 
conditions. However, kinetic studies for the formation and dissolution of RAD51 
foci upon irradiation with 4 Gy revealed no significant differences (Figure S 4). 
In summary, BCL-xL specifically impacts on radiation-induced DSB repair via HRR 
and alt-EJ. Whereas HRR seems to be fundamental for BCL-xL-mediated 
radioresistance, activity of alt-EJ is additionally enhanced in BCL-xL 
overexpressing cells. 
 
 
Figure 23: Long-term survival of A431 cells after combined treatment with irradiation and repair 
inhibitors. (A) A431 cells stably expressing either vector control (Ctrl.) or BCL-xL expression vector were pre-
treated with 2 µM NU7441 or DMSO for 1 h before irradiation with different doses (0 – 10 Gy). After incubation 
for 24 h, medium was changed to inhibitor-free medium and colonies were grown for 11 days. (B) BCL-xL 
overexpressing A431 cells and control cells were pre-treated with 50 µM B02 or DMSO for 1 h before 
irradiation with different doses (0 – 10 Gy). Medium was changed to inhibitor-free medium after 6 h and 
colonies were grown for 11 day. 
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C-NHEJ repair is known to be error-prone, while alt-EJ even amplifies gross 
genomic aberrations (Dueva & Iliakis 2013). Enhanced alt-EJ in irradiated cancer 
cells expressing high levels of BCL-xL could thus result in the propagation of 
cancer cells with more damaged genomes, which could give rise to resistant and 
more aggressive subclones. To examine whether BCL-xL overexpression 
accumulates chromosomal aberrations, metaphase analyses of cells irradiated 
with 1 Gy were conducted in the presence or absence of NU7441 to favor c-NHEJ 
or alt-EJ. Cells were arrested in metaphase by colcemid treatment at 8 and 20 h 
after irradiation and chromosomes were analyzed microscopically. Figure 24 
shows the mean of all aberrations per metaphase, including chromatid breaks, 
dicentrics, sister unions, chromosomal translocations, and acentric fragments (see 
Figure 24 A for representative images). These data confirm that preferential 
activity of alt-EJ amplifies irradiation-induced formation of chromosomal 
aberrations, as NU7441-treated cells have about twice as much aberrations as 
DMSO control cells. A difference between BCL-xL overexpressing cells and 
control cells was not observed under c-NHEJ conditions (absence of NU7441, 
Figure 24 B, left). On the contrary, the number of radiation-induced chromosomal 
aberrations was significantly increased in A431 cells with BCL-xL overexpression 
in the presence of NU7441 at 8 h after irradiation. However, at the later time point 
(20 h), this difference between BCL-xL and control cells was diminished which 
indicates an involvement of cells in S / G2 phase of the cell cycle and events of 
HRR abrogation that are backed up by alt-EJ. 
In summary, these results suggest that BCL-xL overexpresssion mediates HRR-
dependent resistance against irradiation and fosters the highly error-prone alt-EJ 
pathway, potentially resulting in the accumulation of genomic alterations. 
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Figure 24: Chromosomal aberrations in the presence or absence of NU7441. A431 cells stably 
expressing either vector control (Ctrl.) or BCL-xL vector (BCL-xL) were pre-treated with 5 µM NU7441 for 1 h 
before irradiation with 1 Gy or sham irradiation. Cells were fixed after 8 and 20 h and metaphases were 
prepared. At least 50 metaphases of each sample were analyzed for chromosomal aberrations. 
(A) Representative images of different chromosomal aberrations. (B) Quantification of all chromosomal 
aberrations after different treatments. *** p ≤0.001. 
 
 
5.2.5 Pharmacologic targeting of BCL-2 family members in combination 
with radiotherapy 
Targeting anti-apoptotic BCL-2 family members by genetic or functional 
approaches sensitized lung cancer cells towards irradiation (compare 5.2.3). As 
those approaches are not feasible in the clinics, pharmacological interference with 
those proteins was tested to validate them as therapeutic targets. To this end, 
cells were treated with different BH3-mimetics. BH3-only proteins are a group of 
pro-apoptotic BCL-2 family members, which act upstream of BAX and BAK by 
neutralizing BCL-2-like survival factors (like BCL-xL and MCL-1) (Kirkin et al. 
2004). Several peptides and small molecules have been developed to mimic BH3-
only proteins in order to inhibit anti-apoptotic BCL-2 family members. ABT-737 is a 
small-molecule inhibitor of BCL-2, BCL-xL, and BCL-w, which enhances the 
effects of death signals (Oltersdorf et al. 2005). Although it has been reported that 
ABT-737 itself does not directly initiate the apoptotic process, an increase of dead 
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cells was observed in non-irradiated A549 cells upon ABT-737 treatment (Figure 
25 A). However, additional irradiation of the cells amplified ABT-737-induced cell 
death significantly. Long-term survival after irradiation was marginally decreased 
by ABT-737 treatment (Figure 25 B). 
 
 
Figure 25: Functional block of BCL-2 family members by the BH3-mimetic ABT-737. (A) Irradiation-
induced cell death of A549 cells treated with the BH3-mimetic ABT-737. A549 cells were pretreated with 
12.5 µM ABT-737 for 1 h prior to irradiation with 10 Gy or sham irradiation. Cell death was quantified 72 h 
after irradiation by measuring the cell fraction with subgenomic DNA content using flow cytometry 
(mean + SD, n = 3). (B) Long-term survival of A549 cells treated with 12.5 µM ABT-737 and different doses of 
irradiation. A549 cells were pretreated with ABT-737 for 1 h prior to irradiation and ABT-737 was washed out 
24 h after irradiation. Colonies were grown for 11 d (n=1). 
 
As ABT-737 cannot be used as a therapeutic agent due to its low aqueous 
solubility and poor oral bioavailability, the second-generation BH3-mimetics 
ABT-263 (Navitoclax) and GX15-070 (Obatoclax) were included in this study. 
ABT-263 is orally bioavailable (Tse et al. 2008) and currently under clinical 
development in several cancer entities. Dose response curves for Navitoclax in 
A549 and H1299 cells, achieved from MTT assays, revealed 1 to 2.5 µM to be 
effective but not toxic (Figure S 2). Interestingly, even 0.5 to 1 µM Navitoclax were 
enough to highly sensitize A549 cells to irradiation-induced cell death (Figure 
26 A). Moreover, 1 µM Navitoclax also enhanced the suppression of long-term 
clonogenic survival by radiation therapy of A549 cells (Figure 26 B). In H1299 
cells, higher doses of Navitoclax (5 µM) were necessary to sensitize cells towards 
irradiation in short-term and long-term survival (Figure 26 C, D). 
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Figure 26: Functional block of BCL-2 family members by the bioavailable BH3-mimetic ABT-263. 
(A, C) Irradiation-induced cell death of A549 (A) and H1299 (C) cells in the presence or absence of the BH3-
mimetic ABT-263. Cells were pretreated with indicated doses of ABT-263 for 1 h prior to irradiation with 10 Gy 
or sham irradiation. Cell death was quantified 72 h after irradiation by measuring the cell fraction with 
subgenomic DNA content using flow cytometry (mean + SD, n = 3). (B, D) Long-term survival of A549 (B) and 
H1299 (D) treated with indicated doses of ABT-263 and different doses of irradiation. ABT-263 was added 1 h 
before irradiation and cells were re-seeded for clonogenic survival in medium without ABT-263 24 h after 
irradiation (mean + SD, n = 3). 
 
The third tested BH3-mimetic was Obatoclax. This small molecule is predicted to 
be a pan-BCL-2 inhibitor targeting all six anti-apoptotic BCL-2 family members 
(Zhai et al. 2006). Dose response curves showed that Obatoclax already inhibited 
proliferation in nanomolar concentrations (50 – 100 nM; Figure S 2). However, in 
contrast to Navitoclax, Obatoclax had rather no radiosensitizing effect in A549 and 
H1299 cells. Low concentrations (25 – 50 nM) did not increase irradiation-induced 
cell death significantly. Therefore, higher concentrations (0.5 – 1 µM) were also 
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tested, but the same results were observed in H1299 cells, while the dose was 
already highly toxic in A549 cells (Figure 27). 
 
 
Figure 27: Treatment of A549 and H1299 cells with the pan BH3-mimetic Obatoclax. (A) Irradiation-
induced cell death of A549 cells pre-treated with indicated concentrations of Obatoclax for 1 h before 
irradiation with 10 Gy or sham irradiation. Cell death was measured by determination of cell with subgenomic 
DNA content. (B) Irradiation-induced cell death of H1299 cells analyzed as in A. n.s. p > 0.05. 
 
In summary, different approaches revealed that targeting either BCL-xL or MCL-1 
sensitizes NSCLC cells towards irradiation. However, many cells still survived after 
combining irradiation with BH3-mimetics. Due to this, it was aimed to further 
sensitize cells towards irradiation. As both effective BH3-mimetics ABT-737 and 
Navitoclax do not interfere with MCL-1, which also mediated resistance against 
irradiation (Figure 14), it was hypothesized that simultaneous targeting of BCL-xL 
and MCL-1 should further increase irradiation-induced cell death. To test this, two 
different approaches were followed. In the first setup, BCL-xL knockdown and 
control A549 cells were treated with the synthetic compound flavopiridol, which 
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decreases MCL-1 levels (Ma et al. 2003, Figure 28  A / B left). Co-treatment with 
flavopiridol enhanced the sensitization of A549 and H1299 cells to irradiation-
induced cell death by shRNA-mediated suppression of endogenous BCL-xL 
significantly (Figure 28 A / B right). 
 
 
Figure 28: Combined treatment of BCL-xL and MCL-1 with shRNA knockdown and flavopiridol. 
(A) A549 cells stably expressing a lentiviral shRNA expression vector targeting BCL-xL (shRNA BCL-xL) or a 
control shRNA vector (shRNA scr.) were treated with flavopiridol (FP) to decrease MCL-1 protein levels. Left: 
Validation of MCL-1 decrease upon treatment with 50 and 100 nM FP compared to DMSO-treated cells (C). 
Protein levels were determined by immunoblotting 3 h after treatment. Actin served as a loading control. Right: 
Irradiation-induced cell death of indicated A549 cells, pre-treated with 100 nM FP for 3 h before irradiation with 
10 Gy or sham irradiation. Cell death was measured 72 h after irradiation by determining the cell fraction with 
subgenomic DNA content using flow cytometry (mean + SD, n = 3). (B) H1299 cells stably expressing a 
lentiviral shRNA expression vector targeting BCL-xL (shRNA BCL-xL) or a control shRNA vector (shRNA scr.) 
were treated with FP to decrease MCL-1 protein levels. H1299 cells were treated and analyzed as A549 cells 
in A. n.s. p>0.05, ** p ≤0.01, *** p ≤0.001. 
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To confirm this observation, MCL-1 knockdown and control A549 cells were 
treated with ABT-737. The mimetic alone had again toxic effects as observed 
before and this was more pronounced in cells with MCL-1 knockdown. As 
mentioned above, the combination of ABT-737 and irradiation increased cell death 
and as expected, this was significantly higher in cells with stable MCL-1 
knockdown (Figure 29 A). Interestingly, shRNA-mediated suppression of 
endogenous MCL-1 also further increased radiosensitization of the BH3-mimetic 
ABT-737 in H1299 (Figure 29 B), although MCL-1 knockdown was inefficient in 
those cells (compare Figure 16 D). In general, the combination of BCL-xL 
knockdown and flavopiridol treatment was more effective than MCL-1 knockdown 
and ABT-737 treatment. As shRNA-mediated gene suppression was more 
effective for BCL-xL than for MCL-1 (Figure 16), the observed differences have to 
be interpreted with caution. 
 
 
Figure 29: Combined treatment of BCL-xL and MCL-1 with ABT-737 and shRNA knockdown. A549 (A) 
and H1299 (B) cells stably expressing a lentiviral shRNA expression vector targeting MCL-1 (shRNA MCL-1) 
or a control shRNA vector (shRNA scr.) were pretreated with 5 µM ABT-737 for 1 h followed by irradiation with 
10 Gy or sham irradiation. Cell death was determined by quantifying the cell fraction with subgenomic DNA 
content using flow cytometry (mean + SD, n = 3) * p ≤0.05, ** p ≤0.01, *** p ≤0.001. 
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5.3 Characterization of RAF-1 as a modulator of radiotherapy 
response 
Besides BCL-xL, the signal transduction mediator RAF-1 was identified as a 
strong modulator of the radiotherapy response in the initial screen in A431 cells 
(see 5.1). The following section will further characterize the impact of RAF-1 on 
radiotherapy modulation. 
 
 
5.3.1 Long-term survival after irradiation in the presence of active RAF-1 
To determine radiosensitivity of cells, the most common method is the clonogenic 
survival assay. To analyze the impact of RAF-1 activation on clonogenic survival, 
equal numbers of A431 cells stably transduced with a vector containing 
ΔRAF-1-ERtam were seeded in the presence or absence of 4OHT and irradiated 
with different doses of γ-irradiation (0 – 10 Gy). Colony formation was analyzed 
after 6 d of growing. Figure 30 shows that permanent activation of RAF-1 by 4OHT 
led to inhibition of clonogenic survival. A lower number of colonies were grown in 
non-irradiated controls treated with 4OHT compared to cells without 4OHT 
treatment. Thus, it is questionable whether cells irradiated in the presence or 
absence of activated RAF-1 are comparable. 
 
 
Figure 30: Long-term survival of A431 cells with conditionally active RAF-1. Representative images of 
colony formation of A431 cells stably transduced with ΔRAF-1-ERtam expression vector in the presence or 
absence of 4OHT. Equal numbers of cells were plated and RAF-1 was induced by addition of 100 nM 4OHT. 
After irradiation with indicated doses (0 – 10 Gy), colonies were grown for 6 d. 
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5.3.2 Cell cycle changes upon RAF-1 activation 
To further characterize the modulation of the radiotherapy response by RAF-1, 
irradiation-induced changes in cell cycle distribution of A431 cells transduced with 
conditionally active RAF-1 were analyzed in the presence or absence of 4OHT. 
Upon irradiation, A431 cells with conditionally activatable RAF-1 underwent a 
transient G2-arrest, which was stable from 8 to 24 h post irradiation (Figure 31). 
The induction of RAF-1 activity by 4OHT did not influence this effect. 
 
 
Figure 31: Analysis of cell cycle distribution upon irradiation of A431 cells with conditionally active 
RAF-1. A431 cells stably transduced with ΔRAF-1-ERtam expression vector were treated with 10 Gy or sham 
irradiation in the presence (+ 4OHT) or absence (- 4OHT) of 100 nM 4OHT. Cell cycle distribution was 
analyzed by flow cytometry at indicated time points (0, 4, 8, 24, and 48 h). (A) Representative images of 
histograms. (B-D) Quantification of cells in G1 phase (B), S phase (C), and G2 / M phase (D) after irradiation 
with 10 Gy. (mean + SD, n = 3).  
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Interestingly, it was observed that permanent activation of RAF-1 in non-irradiated 
cells induced cell cycle changes. While cells with inactive RAF-1 (- 4OHT) arrested 
in G1 phase of the cell cycle after 24 h post sham irradiation, possibly due to 
contact inhibition, cells with activated RAF-1 (+ 4OHT) accumulated in G2 phase 
after 24 h post sham irradiation (Figure 32). 
 
 
Figure 32: Analysis of cell cycle distribution in non-irradiated A431 cells with conditionally active 
RAF-1. A431 cells stably transduced with ΔRAF-1-ERtam expression vector were treated with sham irradiation 
in the presence (+ 4OHT) or absence (- 4OHT) of 100 nM 4OHT. Cell cycle distribution was analyzed by flow 
cytometry at indicated time points (0, 4, 8, 24, and 48 h). Quantification of cells in G1 phase (A) and G2 / M 
phase (B) (mean + SD, n = 3). 
 
 
5.3.3 Characterization of cell death mechanisms 
The initial screening experiment using PI exclusion assay revealed that irradiation 
of cells with activated RAF-1 induced less cell death. However, the underlying cell 
death mechanism was not characterized at that point. Therefore, AnnexinV – PI 
double stainings were performed in the presence or absence of 4OHT in irradiated 
A431 cells stably transduced with conditionally activatable RAF-1. Cells were 
stained at multiple time points post irradiation (4, 6.5, 24, and 48 h) to follow 
kinetics of apoptosis. As described above, only a minor fraction of irradiated A431 
cells exhibited externalization of phosphatidylserine, which is a known feature of 
early apoptosis (Figure 33 A / B). The activation of RAF-1 had no impact on this. 
Surprisingly, it was observed that activation of RAF-1 in A431 cells induced 
morphological changes under these experimental settings. While A431 cells with 
inactive RAF-1 (- 4OHT) shared epithelial-like morphologies as parental cells and 
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grew quite dense, A431 cells with active RAF-1 (+ 4OHT) seemed to grow bigger 
in size, had a more spindle-like cell shape with some filopodia, and most 
impressively had a lot of vacuole-like structures in the cell body (Figure 33 C). 
 
 
Figure 33: Analysis of apoptosis induced by irradiation in A431 cells with conditionally active RAF-1. 
A431 cells stably transduced with ΔRAF-1-ERtam expression vector were irradiated with 10 Gy or sham 
irradiation in the presence (+ 4OHT) or absence (- 4OHT) of 100 nM 4OHT. Cell were stained with AnnexinV-
FITC and PI at different time points (4, 6.5, 24 and 48 h) and measured by flow cytometry. (A) Quantification 
of early apoptotic cells (AnnexinV-positive, PI-negative; mean + SD, n = 3). (B) Quantification of late 
apoptotic / necrotic cells (AnnexinV-positive, PI-positive; mean + SD, n = 3). (C) Representative images of 
A431 [ΔRAF-1-ERtam] cells in the presence or absence of 4OHT taken at 72 h post irradiation. 
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5.3.4 Impact of different timing of RAF-1 activation on radiotherapy 
response 
To further rule out the impact of RAF-1 on the radiotherapy response, it was taken 
advantage of the conditional activation system. It was investigated whether 
different timings of RAF-1 activation and de-activation by addition and removal of 
4OHT, respectively, leads to different responses upon irradiation. Immunoblotting 
showed that RAF-1 is activated in the cells, at least, after 1 h of incubation with 
4OHT (Figure 34 A). Removal of 4OHT did not directly result in RAF-1 
deactivation as shown by immunoblotting. Even 98 h after removal of 4OHT, 
RAF-1 was still activated in those cells (Figure 34 B). 
In the first setup, four different timing strategies were tested: 
- presence of 4OHT from seeding till read-out 
- presence of 4OHT from seeding till 1 h post irradiation 
- presence of 4OHT from 1 h before irradiation till 1 h post irradiation 
- presence of 4OHT from 1 h after irradiation till read-out. 
The impact of timing of RAF-1 activation on radiosensitivity was analyzed by PI 
exclusion assay at 72 h after irradiation. Interestingly, there was no significant 
difference between the different timing strategies (Figure 34 C). Cell death was 
always significantly reduced when RAF-1 was activated. Surprisingly, even 
activation after irradiation was enough to protect cells from irradiation-induced cell 
death. 
In the next step, it was further analyzed when RAF-1 has to be activated after 
irradiation to mediate resistance against irradiation. To this end, the effect of 8 
different activation time points was examined: 
- at seeding (20 h before irradiation) 
- directly before irradiation 
- 5 min after irradiation 
- 15 min after irradiation 
- 30 min after irradiation 
- 1 h after irradiation 
- 2 h after irradiation 
- 6 h after irradiation 
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Figure 34: Analysis of different timing of RAF1 activation. (A) Kinetic of RAF-1 activation after addition of 
4OHT. A431 cells stably expressing ΔRAF-1-ERtam were seeded in medium with 0.5 % FBS and treated with 
100 nM 4OHT for indicated time intervals. Protein expression was measured by immunoblotting, actin served 
as a loading control. (B) Kinetic of RAF-1 deactivation after withdrawal of 4OHT. A431 cells stably expressing 
ΔRAF-1-ERtam were treated with 100 nM 4OHT. After 20 h, medium was changed to 4OHT-free medium and 
cells were lysed at indicated time points. Protein expression was measured by immunoblotting, actin served 
as a loading control. (C) Radiation-induced cell death of A431 cells stably transduced with ΔRAF-1-ERtam 
expression vector treated with different timings of 4OHT addition and removal. Cell death was measured at 
72 h after irradiation with 10 Gy. Percentage of PI-positive cells in irradiated cells was normalized to non-
irradiated cells. 1) 100 nM 4OHT was added at seeding, no withdrawal of 4OHT; 2) 100 nM 4OHT was added 
at seeding, withdrawal of 4OHT 1 h after irradiation; 3) 100 nM 4OHT was added 1 h before irradiation, 
withdrawal of 4OHT 1 h after irradiation; 4) 100 nM 4OHT was added 1 h after irradiation, no withdrawal of 
4OHT (mean + SD, n = 3). (D) Radiation-induced cell death of A431 cells stably transduced with 
ΔRAF-1-ERtam expression vector treated with 100 nM 4OHT at different time points after irradiation. Cell death 
was measured as in A. 1) 4OHT was added at seeding; 2) 4OHT was added directly before irradiation; 
3) 4OHT was added 5 min after irradiation; 4) 4OHT was added 15 min after irradiation; 5) 4OHT was added 
30 min after irradiation; 6) 4OHT was added 1 h after irradiation; 7) 4OHT was added 2 h after irradiation; 
8) 4OHT was added 6 h after irradiation (mean + SD, n = 3).  
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As observed before, activation of RAF-1 always reduced radiation-induced cell 
death significantly (Figure 34 D) and only minor differences between the samples 
of diverse activation time points were observed. 
In summary, this shows that timing of RAF-1 activation does not play a role for its 
radioprotective effects, even at 6 h after irradiation activation leads to protection 
against irradiation-induced cell death. However, the results for RAF-1 deactivation 
have to be considered with caution as removal of 4OHT did not directly lead to 
RAF-1 deactivation.  
 
 
5.3.5 Analysis of RAF-1 in vivo 
Another aim of this study was the in vivo validation of potential modulators of the 
radiotherapy response that have been identified in vitro. Therefore, a preliminary 
experiment was performed to test whether conditional activation of RAF-1 is still 
functional in vivo. Tumors were established in the hind limbs of NOD / SCID mice 
by subcutaneous injection of A431 cells stably expressing ΔRAF-1-ERtam. When 
tumors were palpable after 4 days, one group of mice received tamoxifen-
supplemented diet to induce RAF-1 activation in those xenografts. Outgrowth and 
growth rates did not change upon tamoxifen treatment. However, immunoblotting 
of extracts from tumors revealed no induction of RAF-1 by feeding with tamoxifen 
diet (Figure 35). Functionality of the antibody was confirmed by whole cell extracts 
of 4OHT-treated A431 ΔRAF-1-ERtam cells. Furthermore, xenografts with 
AKT-ERtam were established in parallel. Each mouse was injected with A431 
ΔRAF-1-ERtam cells in one limb and A431 AKT-ERtam in the other limb. 
Interestingly, immunoblotting validated functional AKT activation by tamoxifen 
(Figure S 5). Therefore, poor tamoxifen feeding has to be excluded as a reason for 
non-functional RAF-1 activation. Thus, the system has to be optimized before 
investigating the impact of RAF-1 in vivo. 
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Figure 35: RAF-1 activation in tumor xenografts. NOD/SCID mice received subcutaneous injections of 
A431 cells stably transduced with ΔRAF-1-ERtam expression vector. At day 4 after injection, one group was 
fed with tamoxifen diet to induce RAF-1 activation for 7 to 11 d. Expression of proteins in extracts from tumors 
was measured by immunoblotting and compared to whole cell extracts (WCE), actin served as a loading 
control. 
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6 Discussion 
The ultimate goal of all anti-cancer therapies is long-term eradication of tumor 
cells. However to date, this goal is only achievable in patients with early-stage 
tumors and small subgroups of some entities. Despite initial tumor control, 
localized and systemic relapse is frequently observed and has been linked to 
primary and secondary resistance against treatment strategies. To minimize the 
probability that the tumor escapes by developing resistance, dose escalation 
strategies are broadly provided in the clinics. These also comprise advanced 
planning and delivery strategies in photon therapy, and application of alternative 
beam sources like particle therapy (Christodoulou et al. 2014). The limitation factor 
of current radiotherapy protocols is still normal tissue toxicity and standard 
protocols are already administered at the maximum-tolerated doses (Morgan et al. 
2014).  
Another strategy to prevent early resistance is combined treatment of radiation 
with pharmacological agents, so far mostly standard chemotherapeutics like 
cisplatin (Begg et al. 2011; Eberhardt et al. 2015; Albain et al. 2009; Turrisi et al. 
1999). Those protocols are particularly effective in locally advanced cancers like 
NSCLC stage III, and can even achieve cure in some patients. Nevertheless, the 
majority of patients still relapses and dies from the disease (Pignon et al. 2008). 
As there is currently no predictive biomarker for the radiotherapy response 
available, radiosensitization protocols have been developed empirically. All 
clinically active agents that are used for treatment of stage IV disease and show 
an acceptable safety profile when combined with radiation are potentially 
administered. As only a subgroup of patients benefits from those protocols, there 
is an urgent need to develop new treatment strategies. It was hypothesized that an 
improved understanding of the molecular mechanisms leading to radioresistance 
will provide a reasonable basis for patient stratification and the development 
effective treatments.  
Against this background, a systematic study of the functional impact of 
deregulated signal transduction pathways on the radiation sensitivity of cancer 
cells was conducted. By this, two potential modulators of the radiotherapy 
response, namely BCL-2 family members and the RAF-1 kinase, were identified. 
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The results and the suitability of those modulators as drug targets for combined 
treatment strategies will be discussed in the next sections. 
 
 
6.1 Contribution of BCL-2 family members to radiosensitivity 
Current treatment modalities, like chemotherapy, radiotherapy, and targeted 
therapies, operate by either directly blocking cell viability or by indirectly inducing 
tumor cells to kill themselves (Kaufmann & Vaux 2003). According to this, 
treatment efficacy depends fundamentally on intact cell death mechanisms of 
tumor cells. On the contrary, evasion of programmed cell death (apoptosis) is one 
of the hallmarks of cancer (Hanahan & Weinberg 2000) and tumor cells evolve a 
variety of strategies to circumvent cell death (Hanahan & Weinberg 2011) 
including deregulation of BCL-2 family members (Strasser et al. 1997). This 
protein family is described as being involved in tumor initiation, progression, and 
development of resistance against several treatment modalities (e.g. cytotoxic 
drugs, antibodies, T-cells) (Wesarg et al. 2007; Meiler et al. 2012; Stolz et al. 
2008; Kasper, Breitenbuecher, Heidel, et al. 2012; Kasper, Breitenbuecher, Reis, 
et al. 2012; Huber et al. 2005; Ravi et al. 2006; Hähnel et al. 2008; Kutuk & Letai 
2008). 
Fully in line with this, the initial small-scale screen in A431 cells demonstrated a 
significant impact of BCL-xL, an anti-apoptotic member of the BCL-2 family, on 
reduction of irradiation-induced cell death (see 5.1). Concerning their potential 
importance in development of resistance, the radiotherapy modulation by BCL-2 
family members was further characterized. 
BCL-xL-mediated radioresistance was validated by colony formation assays and 
also in tumor-bearing mice in vivo, which proofs its relevance in an organismal 
context (see 5.2.1). Interestingly, this effect was not restricted to BCL-xL, but also 
MCL-1 showed similar results although the regulation of this protein is completely 
different from BCL-xL. MCL-1 presents low protein stability (Maurer et al. 2006; 
Brunelle et al. 2009) and has opposing functions in terms of binding different BH3-
only proteins compared to BCL-xL (L. Chen et al. 2005). Nevertheless, in the 
presence of enforced MCL-1 expression, irradiation-induced cell death was 
significantly reduced and clonogenic survival was enhanced, both demonstrating 
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that MCL-1 also mediates resistance against irradiation (see 5.2.2). This is in line 
with a previous study, which observed MCL-1 stabilization upon overexpression of 
the deubiquitinase ubiquitin-specific protease 9x (USP9x) being responsible for 
radioresistance (Trivigno et al. 2012). 
The results indicate that it is a general feature of anti-apoptotic BCL-2 family 
members to inhibit the efficacy of radiotherapy. However, compared to BCL-xL the 
effect of MCL-1 was less pronounced, possibly due to its consecutive proteasomal 
degradation, which might inherently sustain lower expression levels compared to 
BCL-xL.  
As the NSCLC cell lines A549 and H1299 were endogenously more radioresistant 
than A431 cells, the mediation of resistance could not be validated in those cell 
lines to exclude cell line specific effects. However, this was taken as an advantage 
for studies of radiosensitization by targeting BCL-xL and MCL-1 to exclude 
off-target effects from enforced expression of transgenes. Knockdown of BCL-xL 
and MCL-1 in all three cell lines allowed determining the impact of different genetic 
backgrounds on the effect of radiosensitization. It has been shown before that 
downregulation of MCL-1 or BCL-xL via RNAi increases the sensitivity of tumor 
cells to chemotherapy (Peddaboina et al. 2012; Song et al. 2005). Interestingly, 
A431 and A549 cells showed quite similar results in terms of radiosensitization 
after BCL-xL or MCL-1 knockdown (5.2.3). In contrast, MCL-1 knockdown was 
inefficient in H1299 cells, which might indicate that this cell line is more dependent 
on functional MCL-1 than A431 or A549 cells. Surprisingly, knockdown of one anti-
apoptotic family member was frequently accompanied with upregulation of the 
other (compare Figure 16). This is especially true for upregulated MCL-1 in A549 
cells with stable BCL-xL knockdown and could indicate a reciprocal regulation of 
those two modulators, but additional studies are required to confirm this 
hypothesis. However, these results clearly demonstrate that targeting endogenous 
BCL-xL and/or MCL-1 is a promising strategy to compete radioresistance. 
To further validate this, anti-apoptotic BCL-2 family members were additionally 
targeted on a functional level by conditional overexpression of pro-apoptotic BAK. 
This changes the balance between pro-survival and pro-apoptotic proteins and 
primes the cells for death (Danial & Korsmeyer 2004). As expected, conditional 
BAK expression opposed the BCL-xL- and MCL-1-mediated radioresistance in 
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A549 cells (5.2.3). This was also demonstrated for other treatment modalities 
before (Wesarg et al. 2007). 
In summary, there is strong evidence that the group of anti-apoptotic BCL-2 family 
members confers radioresistance in lung cancer cells. However, the underlying 
mechanisms had to be analyzed and the suitability of those proteins as 
pharmacological targets remained to be elucidated. These aspects will be 
discussed in the following sections. 
 
 
6.1.1 Potential mechanisms of radioresistance mediated by BCL-2 family 
members 
The finding that BCL-xL and MCL-1 reduce irradiation-induced cell death in lung 
cancer cells was expected due to their anti-apoptotic function. Surprisingly, there 
was only a little increase in apoptosis in response to irradiation at doses that 
induced significant cell death and reduced clonogenic survival (Figure 20). Thus, 
the anti-apoptotic function of those proteins could not explain the radioresistant 
effects and additional roles of anti-apoptotic BCL-2 family members in the radiation 
response were considered. 
Since the major cellular responses to ionizing radiation are the activation of cell 
cycle checkpoints and DNA repair pathways (Ross 1999), the influence of BCL-xL 
on these response pathways was exemplarily investigated. As BCL-xL did not 
change radiation-induced transient G2-arrest (Figure 21), it was hypothesized that 
BCL-xL might interfere with DNA repair pathways. 
As described in 2.3.6, there have been some studies published linking BCL-2 
family members to DNA repair pathways (reviewed in Hardwick & Soane 2013; 
Laulier & Lopez 2012). However, most of them focus on BCL-2 itself and the data 
are highly contradictory. 
Repair kinetics assessed by PFGE demonstrated that enforced expression of 
BCL-xL educed a repair benefit under conditions of blocked c-NHEJ. Inhibition of 
c-NHEJ by treatment with NU7441 in PFGE experiments provided conditions 
where alt-EJ is more strongly involved in DSB repair than HRR. It was shown 
before that cells with defective c-NHEJ repair DSBs with slower kinetics which are 
not affected by additional mutations in HRR components (Wang et al. 2001; Iliakis 
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et al. 2004). Under those conditions, BCL-xL cells tended to repair faster, which 
indicated an enhanced activity of alt-EJ in those cells (Figure 22 C). In contrast, 
there was no difference between BCL-xL and control cells under conditions with 
predominating c-NHEJ (Figure 22 B). Analyses of the cellular outcome after 
irradiation, as shown by clonogenic survival assays, revealed that BCL-xL 
mediated resistance was not influenced by inhibition of c-NHEJ. Treatment with 
NU7441 reduced clonogenic survival in BCL-xL and control cells, while the 
survival benefit of BCL-xL cells was still maintained (Figure 23 A). Interestingly, 
conditions that inhibited HRR using B02, a RAD51-specific inhibitor, eliminated 
survival benefits of cells with BCL-xL overexpression in clonogenic survival 
assays, although B02 treatment compromised clonogenic survival less compared 
to NU7441 treatment (Figure 23 B). This could be explained by the observation 
that the majority of DSBs in eukaryotic cells is repaired by c-NHEJ and probably 
only a small subset of DSBs is repaired by HRR (Shrivastav et al. 2008; 
Rothkamm et al. 2003; Mao et al. 2008). Thus, eukaryotic cells seem to be more 
dependent on c-NHEJ than on HRR, which explains stronger survival deficits in 
cells with abrogated c-NHEJ. However, the results show that BCL-xL-mediated 
radioresistance depends on functional HRR. 
End-joining pathways are considered error-prone with alt-EJ even amplifying 
complex genomic alterations (Dueva & Iliakis 2013). As BCL-xL promoted 
enhanced function of alt-EJ in the used cell system, the induction of chromosomal 
aberrations by irradiation in the presence or absence of NU7441 was examined by 
metaphase analyses. As expected, the mean number of chromosomal aberrations 
per cell was increased after irradiation. In line with the enhanced activity of alt-EJ 
in cells with BCL-xL overexpression, the number of radiation-induced gross 
chromosomal aberrations was significantly increased in the presence of NU7441 
in those cells at 8 h, but faded after 20 h (Figure 24). This indicates that cells 
irradiated in S / G2 phase of the cell cycle are the major contributors to those 
effects. Accordingly, it was shown before that alt-EJ function is enhanced in G2 in 
cells with c-NHEJ defects with minor contribution of HRR (Wu, Wang, Wu, et al. 
2008; Wu, Wang, Mussfeldt, et al. 2008). 
In summary, the results of DNA repair experiments suggest a model according to 
which BCL-xL affects both HRR and alt-EJ. BCL-xL-mediated radioresistance 
depends on HRR, but potentially, DSB repair by HRR is not always productive 
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leading to shunting of DSBs to error-prone alt-EJ and therewith accumulation of 
genomic alterations after irradiation. In line with this, there are some hints that 
alt-EJ gains functional relevance when the ‘standard’ repair processes fail on a 
global or local level (Dueva & Iliakis 2013). As the majority of DSBs was shown to 
be repaired by c-NHEJ and accordingly, PFGE revealed no difference between 
BCL-xL and control cells under standard conditions, the quantitative effect of 
BCL-xL-mediated enhancement of alt-EJ activity in a large irradiated tumor bulk 
might be subtle. However, a few surviving cells with gross chromosomal 
aberrations may be enough to give rise to more resistant and aggressive 
subclones leading to relapse. 
The exact mechanism how BCL-xL interferes with different DNA repair pathways 
remains to be elucidated. It seems likely that BCL-xL interacts with DNA repair 
proteins as it was shown before that, for example, BCL-2 binds to KU70, thereby 
disrupting the KU/DNA-PKcs complex (Kumar et al. 2010; Wang et al. 2008). Also 
interaction of BCL-2 with BRCA1 and PARP-1 was shown before, which links it 
with HRR and alt-EJ, respectively. 
 
 
6.1.2 Clinical relevance of BCL-2 family members for radiotherapy 
Several types of cancer are known to have deregulated BCL-2 family members, 
which contributes to tumor initiation, progression, and resistance to different 
treatment strategies (Kirkin et al. 2004; Amundson et al. 2000). Especially MCL-1 
and BCL-xL belong to the most frequently amplified genes in all human cancers 
(Beroukhim et al. 2010), and high expression of both is very common in lung 
cancer (Wesarg et al. 2007; Borner et al. 1999; Berrieman et al. 2005). This 
emphasizes the significance of those proteins for NSCLC. 
This study provided further evidence that BCL-xL and MCL-1 contribute to 
radioresistance in NSCLC. Furthermore, it was shown that targeting of 
endogenously expressed anti-apoptotic BCL-2 proteins by genetic knockdown or 
by conditional expression of BAK sensitized lung cancer cells to irradiation. This 
strongly indicates that BCL-xL and MCL-1 are potential targets for 
pharmacological radiosensitization of lung cancer models. To validate this, 
different BH3-mimetics, which are frequently used to antagonize BCL-xL, were 
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tested. Indeed, ABT-737 and Navitoclax were effective in radiosensitizing A549 
and H1299 cells, although the effects were partly only marginal (5.2.5). This could 
be explained by the non-functional targeting of MCL-1 of those BH3-mimetics 
(Oltersdorf et al. 2005; Tse et al. 2008). It has been shown before that ABT-737 
treatment is ineffective in cells with high MCL-1 protein levels (Wesarg et al. 2007) 
and that acquired resistance to ABT-737 is, at least in part, mediated by 
upregulation of MCL-1 (Yecies et al. 2010). In line with this, upregulation of MCL-1 
was observed in cells with stable BCL-xL knockdown. 
Radiosensitivity was promoted by combining knockdown of MCL-1 with ABT-737 
treatment or by combining knockdown of BCL-xL with flavopiridol-treatment to 
reduce MCL-1 levels. Accordingly, another study demonstrated that concomitant 
targeting of MCL-1 and treatment with BH3-mimetics potentiates cell lethality (van 
Delft et al. 2006; Chen et al. 2007). Thus, combined treatment of BCL-xL and 
MCL-1 might be feasible to achieve the maximal radiosensitization. Here, the 
major limitation is the lack of specific clinically applicable MCL-1 inhibitors. Several 
potential inhibitors operating in an indirect manner (like flavopiridol) lack selectivity 
and might therefore be highly toxic. Recently, new potent and selective small-
molecule MCL-1 inhibitors have been identified (Leverson et al. 2015), but their 
potential as therapeutics remains to be elucidated. 
In conclusion, the results of this study suggest that monotherapeutic irradiation of 
tumors harboring high levels of BCL-xL or MCL-1 may result in generation of 
resistant and more aggressive tumor subclones rather than eradicating the tumor 
due to accumulation of aberrant chromosomes. To circumvent this, molecules 
such as BCL-xL and MCL-1 may serve as rational targets for novel therapy 
strategies combining targeted pharmacotherapy with radiotherapy aiming at long-
term eradication of cancer cells. Translation of this approach into clinical proof-of-
principle is feasible and the clinically developed BH3-mimetic Navitoclax might be 
an applicable compound for this aim (Gandhi et al. 2011; Tan et al. 2011; Rudin et 
al. 2012; Vlahovic et al. 2014). To kill tumor cells, the particular expression profile 
of pro-survival and BH3-only proteins should be examined as it determines the 
required drug target for individual tumors (L. Chen et al. 2005; Certo et al. 2006). 
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6.2 Contribution of RAF-1 to radiosensitivity 
Approximately 30 % of human cancers show an upregulation of the MAPK 
pathway due to either deregulated growth factor receptors or oncogenic RAS 
mutations (Rushworth et al. 2006; Downward 2003). In contrast to this, direct 
mutations of RAF-1 are rather rare (Gollob et al. 2006). 
In NSCLC, overexpression of the epidermal growth factor receptor (EGFR) is 
found in 40 to 80 % (Lynch et al. 2004). Additionally, depending on the 
epidemiological background, 10 to 40 % of NSCLC patients present with activating 
EGFR mutations (Lovly et al. 2015a; Lynch et al. 2004; Paez et al. 2004; Pao et al. 
2004; Kosaka et al. 2004; Shigematsu et al. 2005), which are also frequently 
amplified (Soh et al. 2009). Oncogenic KRAS mutations, which result in 
constitutive activation of the downstream cascade, are found in 15 to 25 % of 
patients with lung adenocarcinoma (Lovly et al. 2015b). Both frequent cancer-
associated aberrations promote RAF-1 phosphorylation as well as activation and 
make RAF-1 an interesting target for future treatment strategies. 
The contribution of RAF-1 to radioresistance has been differentially discussed in 
the literature. Some studies predicted radiosensitizing effects of RAF-1 (Warenius 
et al. 1994; Warenius et al. 1996; Warenius et al. 1998), while others showed 
RAF-1 to mediate radioresistance (Kasid et al. 1987; Kasid et al. 1989; Kasid et al. 
1996; Riva et al. 1995; Grana et al. 2002). However, the underlying mechanisms 
remained to be elucidated. 
Conditionally activatable RAF-1 was included as a model for several mechanisms 
of aberrant activation of the MAPK pathway into the initial small-scale screen for 
identifying potential modulators of the radiotherapy response of NSCLC. 
Interestingly, RAF-1 activation showed one of the strongest death-reducing effects 
upon irradiation (Figure 11) and was therefore investigated in more detail. 
However, the first limitation of this study was that A431 cells stably transduced 
with the conditionally activatable RAF-1-ERtam construct were not able to form 
proper colonies, especially when RAF-1 was activated in the presence of 4OHT 
(5.3.1). This could, at least in part, be explained by cell cycle effects of activated 
RAF-1 (5.3.2). Permanent RAF-1 activation (in the presence of 4OHT) promoted 
accumulation of cells in G2 and therewith might have prevented unlimited cell 
divisions to form proper colonies. It has been shown before that strong induction of 
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ERK signaling due to RAF manipulation results in transcriptional increase of cell 
cycle inhibitors like p21Cip1 and subsequently cell cycle arrest (Woods et al. 1997; 
Kerkhoff & Rapp 1998). In contrast to this, other studies suggested RAF-1 
dependent cell cycle progression (Mielgo et al. 2011). It has been claimed that 
signal intensity of inducible RAF systems triggers either proliferation or cell cycle 
arrest (Wellbrock et al. 2004). 
To test these hypotheses, the impact of different RAF-1 timings was investigated. 
In cell death assays, differential RAF-1 activation and deactivation did not result in 
significant differences in the cellular outcome upon irradiation. RAF-1 activation 
before, during or after irradiation always decreased the number of dead cells 
compared to cells that were not treated with 4OHT (5.3.4). However, the results for 
RAF-1 deactivation have to be considered with caution, as removal of 4OHT did 
not directly lead to RAF-1 deactivation (Figure 34 A, B). For this reason, the 
question whether signal intensity or timing plays a role for RAF-1 function could 
not be answered and colony formation could not be improved. Potentially, 
deactivation was hampered by serum-containing medium. Thus, it is suggested to 
repeat the experiments under serum deprivation.  
The second limitation of the RAF-1 project was the inability to propagate cancer 
cells with conditionally active RAF-1 in vivo. This hampered the validation of 
RAF-1 as a potential radiotherapy modulator in tumor-bearing mice in vivo. As 
AKT induction upon tamoxifen treatment was effective in vivo (Figure S 5), there 
was no explanation for this RAF-1-specific effect and further research is required 
to enlighten this observation. 
Concerning the underlying mechanisms leading to RAF-1-mediated resistance, it 
is only possible to speculate (compare 6.2.1). 
 
 
6.2.1 Potential mechanisms leading to RAF-1-mediated radioresistance 
Recent studies have provided growing evidence that RAF-1 has several kinase-
independent functions, which interfere with different cellular processes like 
apoptosis, cell motility, and cell cycle progression (compare 2.4.1). 
Very recently, Advani et al. demonstrated that RAF-1 also interferes with DNA 
repair in a kinase-independent but phosphorylation-dependent manner. They 
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showed that RAF-1 phosphorylation at Serine 338 (Ser338) mediates 
radioresistance, at least in part, by interacting with the cell cycle checkpoint kinase 
CHK2, promoting its activation and enhancing the DNA damage response, in 
which CHK2 is involved (Advani et al. 2015). Additionally, it has been shown 
before that activation of CHK2 contributes to radioresistance (e.g. Bao et al. 2006; 
Jobson et al. 2009). In the present study, Ser338 was also phosphorylated upon 
addition of 4OHT (Figure 10). Therefore, the described mechanism of CHK2 
activation might be relevant for RAF-1-mediated radioresistance in the model of 
this study. However, the observation that addition of 4OHT 6 h after irradiation 
confers decreased cell death as well as addition before irradiation (see 5.3.4) 
contradicts this hypothesis, as the DNA damage response should be activated 
within a few minutes up to few hours. 
The second hypothesis is that RAF-1 might mediate radioresistance by inhibiting 
cell death, especially apoptosis. It has been shown that RAF-1 inhibits apoptosis 
by specific inactivation of pro-apoptotic kinases ASK (Alavi et al. 2007) and MST2 
(O’Neill et al. 2004). The results of RAF-1 timing experiments could favor this 
hypothesis, as apoptosis is a later effect of irradiation than DNA damage 
response. On the contrary, it was also analyzed whether apoptosis plays a role in 
this radiation context, but only marginal apoptosis-related changes, like 
externalization of phosphatidylserine, were observed upon irradiation (5.3.3). 
Additionally, RAF-1 has been shown to mediate inactivation of pro-apoptotic BAD, 
activation of BCL-2, and stabilization of MCL-1 (Jin et al. 2005; Salomoni et al. 
1998; Yoon et al. 2002). Thus, hypothetically RAF-1 mediates resistance via 
deregulation of BCL-2 family members leading to the effects discussed above 
(6.1.1) 
Surprisingly, RAF-1 activation induced morphological changes (Figure 33 C), 
which might allow another hypothesis of mechanism. Especially, the observation 
of vacuole-like structures was striking and might be a hind for autophagy-related 
effects. 
In summary, further research is needed to clarify the underlying mechanisms 
leading to RAF-1-mediated resistance in the model of this study. It is of special 
interest whether the mechanism depends on kinase activity or phosphorylation 
processes, as this would have a high impact on the development of treatment 
strategies (see 6.2.2). 
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6.2.2 Clinical relevance of RAF-1 for radiotherapy 
Taking into account that the MAPK pathway is aberrantly activated in 
approximately 30 % of human cancers (Rushworth et al. 2006), the clinical 
relevance of its essential mediator RAF-1 in general is not questionable. The 
findings that ionizing radiation promotes phosphorylation of RAF-1 and that anti-
sense strategies for RAF-1 increase radiosensitivity in vitro as well as in some 
patients (Pirollo et al. 1997; Kasid & Dritschilo 2003; Dritschilo et al. 2006) 
additionally supports its impact on the radiotherapy response. However, targeting 
RAF-1 or its downstream targets with kinase inhibitors often fail to radiosensitize 
(Advani et al. 2015; Grana et al. 2002). This highly suggests kinase-independent 
functions of RAF-1 to be responsible for its radioresistant effects. Indeed, allosteric 
RAF-1 inhibitors (e.g. KG5) that block dimerization with BRAF and phosphorylation 
at Ser338 sensitized cells to IR (Advani et al. 2015). The same inhibitor was also 
shown to induce cell cycle arrest by PLK1 (Mielgo et al. 2011). Thus allosteric 
RAF-1 inhibitors would prevent tumor progression and sensitize to therapy. 
Therefore, they are considered being quite promising. Further research is needed 
to develop clinically applicable RAF-1 inhibitors that primarily function in an 
allosteric fashion to inhibit kinase-independent functions of RAF-1.  
 
 
6.3 Conclusion and Outlook 
This study demonstrates that anti-apoptotic BCL-2 family members and RAF-1 
mediate resistance against irradiation and therewith, provides new concepts for 
treatment using biomarker-driven targets in combination with irradiation instead of 
empirically driven protocols of chemoradiotherapy. 
The underlying mechanism for BCL-2 family members is, at least in part, the 
enhancement of repair kinetics for radiation-induced DSBs via the error-prone 
alt-EJ pathway. Thus, irradiation of tumors with BCL-2 family deregulation could 
promote tumor progression, which emphasizes the importance of rational 
biomarker profiling of each individual tumor before treatment. Tumors with 
overexpression of anti-apoptotic BCL-2 family members should be irradiated in 
combination with concomitant targeting of BCL-xL and MCL-1, if clinically feasible. 
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The underlying mechanisms for RAF-1-mediated radioresistance still remain to be 
elucidated. In order to develop new treatment protocols combining radiotherapy 
with targeted therapies against RAF-1, it is of special interest to work out whether 
RAF-1-mediated resistance is a kinase-dependent or kinase-independent 
phenomenon. 
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8 Appendix 
8.1 Supplementary figures 
 
 
Figure S 1: Impact of different transgenes on irradiation-induced cell death (48 h). A431 cells stably 
expressing indicated transgenes were stained with PI 48 h after irradiation with indicated doses (0 – 10 Gy) 
and the fraction of PI-positive cells was determined by flow cytometry (mean + SD, n = 3). * p ≤0.05, 
** p ≤0.01, *** p ≤0.001. 
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Figure S 2: Treatment with ABT-263 and Obatoclax. (A, B) Relative proliferation of A549 cells treated with 
different concentrations of ABT-263 (A) or Obatoclax (B) was measured by MTT assay in comparison to non-
treated cells after 72 h (mean + SD, n = 2). (C, D) Relative proliferation of H1299 cells treated with different 
concentrations of ABT-263 (C) or Obatoclax (D) was measured by MTT assay in comparison to non-treated 
cells after 72 h (mean + SD, n = 2). 
 
 
 
Figure S 3: Validation of decrease of RAD51 foci after B02 treatment. A431 cells stably expressing 
BCL-xL or empty vector control were pre-treated with 50 µM B02 or DMSO for 1 h before irradiation with 4 Gy. 
After 3 h, cells were fixed and immunostaining was performed to visualize RAD51 foci and Cyclin B1. 
(A) Representative images of control cells (blue: DAPI, red: Cyclin B1, green: RAD51). (B) Quantification of 
Rad51 foci in Cyclin B1-positive cells (S/G2 cells). 
 
  
 
8 Appendix 
 
  
128 
 
Figure S 4: RAD51 foci formation upon irradiation. A431 cells stably expressing BCL-xL or empty vector 
control were irradiated with 4 Gy or sham irradiation and fixed at indicated time points (1 – 18 h). 
Immunostaining was performed to visualize RAD51 foci and Cyclin B1. Numbers of Rad51 foci were only 
counted in Cyclin B1-positive cells (S / G2 cells). 
 
 
 
Figure S 5: AKT activation in tumor xenografts. NOD/SCID mice received subcutaneous injections of A431 
cells stably transduced with AKT-1-ERtam expression vector. At day 4 after injection, one group was fed with 
tamoxifen diet to induce AKT activation for 11 d. Expression of proteins in extracts from tumors was measured 
by immunoblotting and compared to whole cell extracts (WCE), actin served as a loading control. 
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8.2 Materials 
8.2.1 Cell lines and bacteria 
8.2.1.1 General cell lines 
cell lines source 
A431 DSMZ, Braunschweig, Germany  
A549 Schuler lab, University Hospital Essen, Germany 
FNX Nolan lab, Stanford University, USA  
H1299 Schuler lab, University Hospital Essen, Germany 
HEK293T DSMZ, Braunschweig, Germany  
 
 
8.2.1.2 Stably transduced cell lines 
cell lines abbreviation source 
A431 [pBabePuro] A431 [Puro] established in this 
project 
A431 [pBabePuro_bcl-xL] A431 [BCL-xL] established in this 
project 
A431 [pBabePuro_Δraf-1-Ertam] A431 [Raf-1-Ertam] established in this 
project 
A431 [pBabePuro_K-RAS_G12V] A431 [K-RAS_G12V] S. Kasper 
A431 [pBabePuro_K-RAS_WT] A431 [K-RAS_wt] S. Kasper 
A431 [pLKO.1-puro_scrambled] A431 [shRNA scr.] established in this 
project 
A431 
[pLKO.1-puro_TRCN0000005514] 
A431 [shRNA MCL-1_1] P. Craigmile 
A431 
[pLKO.1-puro_TRCN0000005515] 
A431 [shRNA MCL-1_2] P. Craigmile 
A431 
[pLKO.1-puro_TRCN0000005516] 
A431 [shRNA MCL-1_3] P. Craigmile 
A431 
[pLKO.1-puro_TRCN0000005517] 
A431 [shRNA MCL-1_4] P. Craigmile 
A431 
[pLKO.1-puro_TRCN0000005518] 
A431 [shRNA MCL-1_5] P. Craigmile 
A431 
[pLKO.1-puro_TRCN0000033499] 
A431 [shRNA BCL-xL_1] established in this 
project 
A431 
[pLKO.1-puro_TRCN0000033500] 
A431 [shRNA BCL-xL_2] established in this 
project 
A431 
[pLKO.1-puro_TRCN0000033501] 
A431 [shRNA BCL-xL_3] established in this 
project 
A431 
[pLKO.1-puro_TRCN0000033502] 
A431 [shRNA BCL-xL_4] established in this 
project 
A431 
[pLKO.1-puro_TRCN0000033503] 
A431 [shRNA BCL-xL_5] established in this 
project 
A431 [pMx-pie-Mcl-1 ] A431 [MCL-1] S. Kasper 
A431 [pQC_HPV16-E7_IN] A431 [E7] M. Pogorzelski 
A431 [pQC_mAkt-HA-Ertam_IP] A431 [AKT-Ertam] S. Kasper 
A431 [QCXIN_HPV16_E6] A431 [E6] M. Pogorzelski 
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cell lines abbreviation source 
A549 [pLKO.1-puro_scrambled] A549 [shRNA scr.] established in this 
project 
A549 
[pLKO.1-puro_TRCN0000005514] 
A549 [shRNA MCL-1_1] P. Craigmile 
A549 
[pLKO.1-puro_TRCN0000005515] 
A549 [shRNA MCL-1_2] P. Craigmile 
A549 
[pLKO.1-puro_TRCN0000005516] 
A549 [shRNA MCL-1_3] P. Craigmile 
A549 
[pLKO.1-puro_TRCN0000005517] 
A549 [shRNA MCL-1_4] P. Craigmile 
A549 
[pLKO.1-puro_TRCN0000005518] 
A549 [shRNA MCL-1_5] P. Craigmile 
A549 
[pLKO.1-puro_TRCN0000033499] 
A549 [shRNA BCL-xL_1] established in this 
project 
A549 
[pLKO.1-puro_TRCN0000033500] 
A549 [shRNA BCL-xL_2] established in this 
project 
A549 
[pLKO.1-puro_TRCN0000033501] 
A549 [shRNA BCL-xL_3] established in this 
project 
A549 
[pLKO.1-puro_TRCN0000033502] 
A549 [shRNA BCL-xL_4] established in this 
project 
A549 
[pLKO.1-puro_TRCN0000033503] 
A549 [shRNA BCL-xL_5] established in this 
project 
A549 
[pQC_rtTA-M2_IP, pRevTRE_BAK] 
A549 [tet_BAK] S. Hoffarth 
A549 [pQC_rtTA-M2_IP] A549 [rtTA] S. Hoffarth 
H1299 [pLKO.1-puro_scrambled] H1299 [shRNA scr.] established in this 
project 
H1299 
[pLKO.1-puro_TRCN0000005514] 
H1299 [shRNA MCL-1_1] P. Craigmile 
H1299 
[pLKO.1-puro_TRCN0000005515] 
H1299 [shRNA MCL-1_2] P. Craigmile 
H1299 
[pLKO.1-puro_TRCN0000005516] 
H1299 [shRNA MCL-1_3] P. Craigmile 
H1299 
[pLKO.1-puro_TRCN0000005517] 
H1299 [shRNA MCL-1_4] P. Craigmile 
H1299 
[pLKO.1-puro_TRCN0000005518] 
H1299 [shRNA MCL-1_5] P. Craigmile 
H1299 
[pLKO.1-puro_TRCN0000033499] 
H1299 [shRNA BCL-xL_1] established in this 
project 
H1299 
[pLKO.1-puro_TRCN0000033500] 
H1299 [shRNA BCL-xL_2] established in this 
project 
H1299 
[pLKO.1-puro_TRCN0000033501] 
H1299 [shRNA BCL-xL_3] established in this 
project 
H1299 
[pLKO.1-puro_TRCN0000033502] 
H1299 [shRNA BCL-xL_4] established in this 
project 
H1299 
[pLKO.1-puro_TRCN0000033503] 
H1299 [shRNA BCL-xL_5] established in this 
project 
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8.2.2 qPCR primers 
gene sequence (5’  3’) supplier 
Actin sense: GGATTCCTATGTGGGCG 
antisense: GGCGTACAGGGATAGC 
Eurofins MWG 
E6 sense: TTGCTTTTCGGGATTTATGC 
antisense: 
CAGGACACAGTGGCTTTTGA 
Eurofins MWG 
E7 sense: CAGCTCAGAGGAGGAGGATG 
antisense: 
GCCCATTAACAGGTCTTCCA 
Eurofins MWG 
 
 
8.2.3 Plasmids 
8.2.3.1 Packaging plasmids 
plasmid name function origin 
Hit60 (MLV gag-pol) retroviral polymerase C. Benedict 
pCMV.VSV-G retroviral envelope W. Nishioka 
pMD2 lentiviral envelope Scholl/Fröhling – Ulm 
pSPAX lentiviral polymerase Scholl/Fröhling – Ulm 
 
 
8.2.3.2 Retroviral plasmids of interest 
plasmid name function origin 
pLPC_EGFP GFP control M. Schuler 
pBabePuro empty vector control C. Benedict 
pBabePuro_bcl-xL BCL-xL overexpression J. Goldstein 
pBabePuro_Δraf-1-Ertam conditional RAF1 activation S. Cook 
 
 
8.2.3.3 Lentiviral plasmids of interest 
plasmid name function origin 
pHRST-ires-GFP GFP control J.-S. Lee 
pLKO.1-puro_scrambled shRNA scrambled Scholl/Fröhling – Ulm 
pLKO.1-
puro_TRCN0000005514 
shRNA MCL-1_1 P. Hähnel 
pLKO.1-
puro_TRCN0000005515 
shRNA MCL-1_2 P. Hähnel 
pLKO.1-
puro_TRCN0000005516 
shRNA MCL-1_3 P. Hähnel 
pLKO.1-
puro_TRCN0000005517 
shRNA MCL-1_4 P. Hähnel 
pLKO.1-
puro_TRCN0000005518 
shRNA MCL-1_5 P. Hähnel 
pLKO.1-
puro_TRCN0000033499 
shRNA BCL-xL_1 Sigma-Aldrich 
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plasmid name function origin 
pLKO.1-
puro_TRCN0000033500 
shRNA BCL-xL_2 Sigma-Aldrich 
pLKO.1-
puro_TRCN0000033501 
shRNA BCL-xL_3 Sigma-Aldrich 
pLKO.1-
puro_TRCN0000033502 
shRNA BCL-xL_4 Sigma-Aldrich 
pLKO.1-
puro_TRCN0000033503 
shRNA BCL-xL_5 Sigma-Aldrich 
 
 
8.2.4 Antibodies 
8.2.4.1 Primary antibodies for immunoblotting 
antibody species dilution source 
anti-Mcl-1 rabbit 1:1000 EPITOMICS (#1239-1) 
anti-phospho-Akt(Ser473) rabbit 1:1000 Cell Signaling (#9271) 
anti-Ras rabbit 1:1000 Cell Signaling (#3965) 
anti-cRaf rabbit 1:1000 Cell Signaling (#9422) 
anti-phospho-cRaf(Ser338) rabbit 1:1000 Cell Signaling (#9427) 
anti-AKT rabbit 1:1000 Cell Signaling (#9272) 
anti-BCL-xL (54H6) rabbit 1:1000 Cell Signaling (#2764) 
anti-actin (clone C4) mouse 1:10000 MP Biomedicals (#69100) 
anti-Bak rabbit 1:1000 Upstate (#06-536) 
 
 
8.2.4.2 Secondary antibodies for immunoblotting 
antibody dilution source 
anti-mouse-HRP 1:2000 Thermo Scientific 
anti-rabbit-HRP 1:2000 Thermo Scientific 
 
 
8.2.4.3 Primary antibodies for immunofluorescence 
antibody species dilution  source 
anti-Rad51 (14B4) mouse 1:500 GeneTex (GTX70230) 
anti-CyclinB1 (H433) rabbit 1:150 Santa Cruz (sc-752) 
 
 
8.2.4.4 Secondary antibodies for immunofluorescence 
antibody dilution source 
goat-anti-rabbit-Alexa568 1:400 life technologies 
goat-anti-mouse-Alexa488 1:400 life technologies 
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8.2.5 Kits and Mixes 
FITC Annexin V Apoptosis Detection Kit BD Biosciences (US) 
High Pure RNA Isolation Kit Roche (CH) 
Light Cycler ® 480 SYBR Green Master Kit Roche (CH) 
Plasmid Plus Maxi Kit QIAGEN (NL) 
Protein Assay Dye Reagent Concentrate BioRad (US) 
Sorenson’s buffer Gibco, life technologies (US) 
Super Signal West Pico system  Thermo Scientific (US) 
Transcriptor High Fidelity cDNA Synthesis Kit Roche (CH) 
 
 
8.2.6 Cell culture materials 
ABT-263 (Navitoclax) Cayman (US) 
ABT-737 Abbott Laboratories (US) 
B02 Calbiochem, Merck KgaA (D) 
Colcemid Biochrom, Merck KgaA (D) 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich (US) 
DMEM (high glucose, no glutamine) Gibco, life technologies (US) 
Doxycycline Sigma-Aldrich (US) 
DPBS (no calcium, no magnesium) Gibco, life technologies (US) 
FBS Biochrom, Merck KgaA (D) 
4-Hydroxytamoxifen (4OHT) Sigma-Aldrich (US) 
L-Glutamine (200 mM) Gibco, life technologies (US) 
Matrigel (growth factor reduced, phenol red-free) Corning (US) 
NU7441 Tocris Bioscience (US) 
Penicillin-Streptomycin (10,000 U/ml) Gibco, life technologies (US) 
Puromycin, Dihydrochloride Calbiochem, Merck KgaA (D) 
RPMI 1640 (no glutamine) Gibco, life technologies (US) 
0.4% Trypan blue Invitrogen, life technologies (US) 
Trypsin-EDTA (0.05%, phenol red) Gibco, life technologies (US) 
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8.2.7 Chemicals 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) Sigma-Aldrich (US) 
Acetic acid Roth (D) 
Acrylamide mix Rotiphorese® Gel 30 (37.5:1) Roth (D) 
Ammonium peroxodisulfate Roth (D) 
Boric acid Roth (D) 
Brilliant blue Roth (D) 
Bromophenol blue Merck KgaA (D) 
BSA fraction V Roth (D) 
Calcium chloride (CaCl2) Roth (D) 
Circlegrow ® medium (Capsules) MP Biomedicals (US) 
cOmplete Protease Inhibitor Cocktail Roche (CH) 
Dry milk (blotting grade) Roth (D) 
Entellan® Merck KgaA (D) 
EDTA Roth (D) 
EGTA Roth (D) 
Ethidium bromide Roth (D) 
Gelatin from porcine skin Sigma-Aldrich (US) 
Gelatin from cold water fish skin Sigma-Aldrich (US) 
Giemsa Roth (D) 
Glucose Roth (D) 
Glycerol Roth (D) 
Glycine Roth (D) 
HEPES Roth (D) 
Nonidet® P40 Substitute (NP40) Fluka, Sigma-Aldrich (US) 
Low Melting Agarose  Roth (US) 
2-Mercaptoethanol Sigma-Aldrich (US) 
Methanol J. T. Baker, VWR (US) 
N-laurylsarcosine Merck KgaA (D) 
PageRuler Prestained Protein Ladder Thermo Scientific (US) 
Paraformaldehyde Roth (D) 
Phosphatase Inhibitor Cocktail 2/3  Sigma-Aldrich (US) 
Ponceau S Roth (D) 
Potassium chloride (KCl) Roth (D) 
PromoFluor Antifade reagent  PromoKine (D) 
Propidium iodide Fluka, Sigma-Aldrich (US) 
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RNAse A Sigma-Aldrich (US) 
SDS Roth (Karlsruhe, D) 
SeaKem LE Agarose  Lonza (CH) 
Sodium chloride (NaCl) Roth (D) 
Sodium citrate Roth (D) 
Sodium hydrogen phosphate Roth (D) 
TEMED Roth (D) 
Tris Roth (D) 
Triton-X100 Roth (D) 
Tween20 Roth (D) 
 
 
8.2.8 Consumables and laboratory equipment 
(standard equipment not listed) 
 
ChemiSmart Imaging System  Vilber Lourmat (F) 
Co-60 γ-ray machine Philips (NL) 
CountessTM Automated Cell Counter Invitrogen, life technologies (US) 
CountessTM Cell Counting Chamber Slide Invitrogen, life technologies (US) 
Coverslips (20 mm diameter) VWR (US) 
Coverslips (24 mm x 60 mm) Roth (D) 
FC500 Flow Cytometer Beckman Coulter (US) 
Gene Quant Pro spectrophotometer GE Healthcare (GB) 
glass slides (76 x 26 mm) Roth (D) 
microscope slides (cut, color frosted) VWR (US) 
Hybond ECL 0.45 µm nitrocellulose membranes GE Healthcare (GB) 
Leica DMR fluorescence microscope Leica (D) 
LightCycler® 480 System Roche (CH) 
MagNA Lyser Instrument Roche (CH) 
Mini-PROTEAN electrophoresis system  BioRad (US) 
Mini-Trans Blot ® Cell tank blot system  BioRad (US) 
Minisart ® 0.2 µm filter  Sartorius Stedim Biotech (D) 
NanoDrop lite spectrophotometer Thermo Scientific (US) 
Nunc ® cell scraper Thermo Scientific (US) 
Olympus CKX41 microscope Olympus (JP) 
QuantiFire XI camera  Intas (D) 
Trans-Blot® Turbo™ Transfer System  BioRad (US) 
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Typhoon 9410 Imager GE-Healthcare (GB) 
Vanix-T bright field microscope Olympus (JP) 
 with Vimba Marlin F046B camera 
X-ray machine GE Healthcare (GB) 
 
 
8.2.9 Material for mouse experiments 
Electronic Digital Caliper (VWRI819-0013) Control Company (US) 
NOD/SCID mice Charles River Laboratories (US) 
Tamoxifen Diet (2016, 400), Pellet, irradiated Harlan (NL) 
 
 
8.2.10 Software 
Adobe Illustrator CS3 Adobe Systems (US) 
Adobe Photoshop CS3 Adobe Systems (US) 
GraphPad Prism (Version 6) GraphPad Software (US) 
ImageJ Wayne Rasband (NIH, US) 
Image-Quant GE Healthcare (GB) 
Imaris (8.0.2) Bitplane (CH) 
SigmaPlot (Version 13) Systat Software Inc (US) 
 
 
8.2.11 Standard buffers 
 
5x transfer buffer 
 
29 g Tris 
14.5 g Glycine 
1.85 g SDS 
 
adjust pH to 9.0 
add A. dest. To 1 l 
add 20 % methanol when diluting 
 
 
 
 
5x SDS running buffer 
 
15.1 g Tris 
72 g Glycine 
5 g SDS 
 
add A. dest. To 1 l 
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6x SDS loading buffer 
 
600 mM Tris-HCl, pH 6.8 
24 % SDS 
20 %  glycerol 
200 mM 2-Mercaptoethanol 
0.2 % Bromophenol blue 
 
NP40 lysis buffer 
 
1 % NP40 
150 mM NaCl 
50 mM HEPES, pH 7.4 
1 mM EDTA 
2 mM EGTA 
 
add 40 µl/ml cOmplete Protease Inhibitor Cocktail, 
10 µl/ml Phosphatase Inhibitor Cocktail 2, 
10 µl/ml Phosphatase Inhibitor Cocktail 3 
 
 
2x HBS 
 
280 mM NaCl 
10 mM KCl 
1.5 mM Na2HPO4 
12 mM glucose 
50 mM HEPES 
 
adjust pH=7.0 
filtered with 0.22 µm filter 
HFS buffer 
 
5 mg propidium iodide 
100 mg sodium citrate 
100 µl Triton-X100 
 
add 100 ml A. dest. 
 
 
Stripping Buffer 
 
62.5 mM Tris-HCl (pH 6.8) 
2 % SDS 
 
 
 
MTT solubilization buffer 
 
0.01 M HCl (38 %) 
10 % SDS 
 
 
 
8.2.12 Standard solutions 
 
stacking gel solution 
 
5 % acrylamide mix  
126 mM Tris-HCl, pH 6.8 
0.1 % SDS 
0.1 % APS 
0.1 % TEMED 
 
 
resolving gel solution 
 
10 % acrylamide mix  
380 mM Tris-HCl pH 8.8 
0.1 % SDS 
0.1 % APS 
0.04 % TEMED 
 
Ponceau S 
 
0.2 % Ponceau S  
5 % Acetic Acid 
 
Blotto 
 
50 g dry milk (fat free) 
1 % Tween 20 
 
add 1 l PBS 
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10x NET-G 
 
1.5 M NaCl 
50 mM EDTA 
500 mM Tris-HCl, pH 7.5 
0.5 % Tween 20 
0.4 % Gelatin (from 
porcine skin) 
 
Colony staining solution 
 
0.25 % Brilliant blue 
10 % Acetic acid 
40 % Methanol 
 
 
 
8.2.13 Buffers for PFGE 
 
lysis buffer 
 
10 mM Tris 
100 mM EDTA 
50 mM NaCl 
2 % N-laurylsarcosine 
 
adjust pH to 7.6 
add 0.2 mg/ml protease directly before use 
 
 
washing buffer 
 
10 mM Tris 
100 mM EDTA 
50 mM NaCl 
 
adjust pH to 7.6 
add 0.1 mg/ml RNAse A directly before use, if 
necessary 
5x TBE 
 
445 mM Tris 
445 mM boric acid 
10 mM EDTA 
 
 
 
 
8.2.14 Buffers for immunofluorescence 
 
P-Solution 
 
100 mM Tris-HCl, pH 7.4 
50 mM EDTA 
0.5 % Triton-X100 
 
PBG 
 
0.2 % 
Gelatin (from cold 
water fish skin) 
0.5 % BSA fraction V 
 PBS 
 
 
 
8.2.15 Buffers for metaphase analysis 
 
hypotonic solution 
 
75 mM KCl 
 
Carnoy’s fixative 
 
3x methanol 
1x acetic acid 
 
  
 
8 Appendix 
 
  
139 
8.3 List of figures 
Figure 1: Schematic drawing of IR tracks through a cell nucleus. 14 
Figure 2: Schematic drawing of HRR pathway. 16 
Figure 3: Schematic drawing of c-NHEJ. 19 
Figure 4: Schematic drawing of alt-EJ. 21 
Figure 5: Schematic drawing of sequence homology of different BCL-2 
subgroups. 24 
Figure 6: Schematic drawing of interaction of BCL-2 family members in the 
unified model. 29 
Figure 7: Representative image of cell cycle profile. 46 
Figure 8: Representative dose response curve of PFGE. 50 
Figure 9: Activation mechanism of conditionally activatable transgenes. 56 
Figure 10: Validation of transgene expression and activation. 57 
Figure 11: Impact of different transgenes on irradiation-induced cell death. 58 
Figure 12: Long-term survival of A431 cells with enforced BCL-xL 
expression. 60 
Figure 13: Relative impact of irradiation on tumor growth of BCL-xL 
overexpressing xenografts compared to control. 61 
Figure 14: MCL-1-mediated resistance against irradiation. 62 
Figure 15: Resistance of NSCLC cells against irradiation. 63 
Figure 16: Expression of BCL-xL and MCL-1 in cells with knockdown. 64 
Figure 17: Sensitization of A549 and A431 cells to IR by knockdown of 
BCL-xL and MCL-1. 65 
Figure 18: Sensitization of H1299 cells to IR by knockdown of BCL-xL. 66 
Figure 19: Functional block of BCL-xL by conditional overexpression of pro-
apoptotic BAK. 67 
Figure 20: Analysis of apoptosis induced by irradiation. 68 
Figure 21: Analysis of cell cycle distribution upon irradiation. 69 
Figure 22: Analysis of DSB repair kinetics as a function of BCL-xL 
expression. 71 
Figure 23: Long-term survival of A431 cells after combined treatment with 
irradiation and repair inhibitors. 72 
  
 
8 Appendix 
 
  
140 
Figure 24: Chromosomal aberrations in the presence or absence of 
NU7441. 74 
Figure 25: Functional block of BCL-2 family members by the BH3-mimetic 
ABT-737. 75 
Figure 26: Functional block of BCL-2 family members by the bioavailable 
BH3-mimetic ABT-263. 76 
Figure 27: Treatment of A549 and H1299 cells with the pan BH3-mimetic 
Obatoclax. 77 
Figure 28: Combined treatment of BCL-xL and MCL-1 with shRNA 
knockdown and flavopiridol. 78 
Figure 29: Combined treatment of BCL-xL and MCL-1 with ABT-737 and 
shRNA knockdown. 79 
Figure 30: Long-term survival of A431 cells with conditionally active RAF-1. 80 
Figure 31: Analysis of cell cycle distribution upon irradiation of A431 cells 
with conditionally active RAF-1. 81 
Figure 32: Analysis of cell cycle distribution in non-irradiated A431 cells with 
conditionally active RAF-1. 82 
Figure 33: Analysis of apoptosis induced by irradiation in A431 cells with 
conditionally active RAF-1. 83 
Figure 34: Analysis of different timing of RAF1 activation. 85 
Figure 35: RAF-1 activation in tumor xenografts. 87 
 
 
Figure S 1: Impact of different transgenes on irradiation-induced cell death 
(48 h). 126 
Figure S 2: Treatment with ABT-263 and Obatoclax. 127 
Figure S 3: Validation of decrease of RAD51 foci after B02 treatment. 127 
Figure S 4: RAD51 foci formation upon irradiation. 128 
Figure S 5: AKT activation in tumor xenografts. 128 
 
  
 
8 Appendix 
 
  
141 
8.4 List of abbreviations 
 
4OHT 4-hydroxytamoxifen 
A. dest. Aqua destillata 
alt-EJ alternative end-joining 
ATM ataxia telangiectasia mutated 
ATR ATM and Rad3-related 
ATRIP ATR-interacting protein 
BAD BCL-2-associated agonist of cell death 
BAK BCL-2 antagonist / killer 
BAX BCL-2-associated X protein 
BBC3 BCL-2 binding component 3 
BCL-2 B-cell lymphoma 2 
BCL-xL B-cell lymphoma extra-large 
BER base excision repair 
BH BCL-2 homology 
BID BH3 interacting domain death agonist 
BLM Bloom’s syndrome protein 
BOK BCL-2-related ovarian killer 
BRCA1 breast cancer 1 
CDK cyclin-dependent kinase 
cDNA complementary deoxyribonucleic acid 
c-NHEJ classical non-homologous end-joining (DNA-PK-dependent) 
CR conserved region 
CtIP C-terminal binding interacting protein 
ctrl. Control 
DDR DNA damage response 
DEQ dose equivalent 
D-loop displacement loop 
DMEM Dulbecco’s modified eagle medium 
DMSO Dimethyl sulfoxide 
DNA deoxyribonucleic acid 
DNA-PK DNA-dependent protein kinase 
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DNA-PKcs catalytic subunit of DNA-dependent protein kinase 
dNTP deoxynucleotide 
Dox doxycycline 
DPBS Dulbecco’s phosphate-buffered saline 
DSB double-strand break 
EDTA Ethylenediaminetetraacetic acid 
EGFR epidermal growth factor receptor 
ER estrogen receptor 
Exo1 exonuclease 1 
FBS fetal bovine serum 
FDR fraction of DNA released 
GFP green fluorescent protein 
GOI gene of interest 
Gy Gray 
H1 histone 1 
HRR homologous recombination repair 
IR ionizing radiation 
LET linear energy transfer 
LigIV ligase IV 
MAPK mitogen-activated protein kinase 
MCL-1 myeloid cell leukemia 1 
MOMP mitochondrial outer membrane permeabilization 
MRE11 meiotic recombination 11 
mRNA messenger ribonucleic acid 
MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide 
NBS1 Nijmegen breakage syndrome 1 
NER nucleotide excision repair 
NOD / SCID non-obese diabetic severe combined immunodeficiency 
NSCLC non-small-cell lung cancer 
PARP-1 Poly (ADP-ribose) polymerase 1 
PFGE pulsed-field gel electrophoresis 
PI propidium iodide 
PIKK phosphatidylinositol 3-kinase-related kinase 
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POI plasmid of interest 
PS phosphatidylserine 
qPCR quantitative polymerase chain reaction 
RAS rat sarcoma protein 
RPA replication protein A 
RPMI Roswell Park Memorial Institute 
RTK receptor tyrosine kinase 
SD standard deviation 
shRNA short hairpin RNA 
SSB single-strand break 
ssDNA single-stranded DNA 
TKI tyrosine kinase inhibitor 
TM transmembrane 
USP9x ubiquitin-specific protease 9x 
WCE whole cell extract 
WRN Werne syndrome protein 
wt wildtype 
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